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Diacylglycerol kinases (DGK) are a family of lipid kinases that phosphorylate 
diacylglycerol (DAG) to produce phosphatidic acid (PA).  DAG and PA are two lipids 
with functions as metabolic intermediates as well as second messengers, which allows 
integrated control of lipid metabolism with nutrient sensing and cell growth.  Both 
lipids lie at the core of tumor-promoting axes, but their contribution to the transformed 
phenotype has not been thoroughly determined. 
Our aim was to determine the input of DGK α and ζ isoforms to breast cancer 
progression and maintenance, to identify new therapeutic approaches for this disease.  
We found that the two isoforms differed in their expression patterns and function.  
DGKα gene expression correlated inversely with activation of the PI3K-Akt-FoxO 
pathway; thus, it was expressed strongly in untransformed breast-derived cell lines.  In 
contrast, DGKζ expression was stronger in transformed cells. 
DGKα and DGKζ used several mechanisms to promote breast cancer 
progression.  DGKζ-dependent DAG consumption was necessary for the maintenance 
of lipid metabolism in breast tumors, via control of the SREBP-1 transcription factor.  
We found that DGK-generated PA was needed for the supply of substrates and for 
maintenance of phosphotyrosine signals that fuel the PI3K-Akt-mTOR axis.  Moreover, 
we show that DGKα and DGKζ were upstream regulators of mTORC1, but only 
DGKα modulated Akt activation as well as that of the Src tyrosine kinase. 
DGK inhibition reduced tumor growth in vitro and in vivo, without switching on 
other signaling pathways that could provide therapeutic resistance, such as the ERK or 
HIF-1α axes.  Finally, we demonstrate that DGKα depletion in highly malignant breast 
cancer-derived cells impaired tumor development in vivo, as assessed in a mouse 
xenograft model. 
Our data show important roles for the DGKα and DGKζ isoforms in promoting 
tumor progression, and suggest that the DGK pathway could represent an effective 
target for anti-cancer therapies. 
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Las diacilglicerol quinasas (DGK) son una familia de lípido quinasas que 
fosforilan el diacilglicerol (DAG) para producir ácido fosfatídico (PA).  El DAG y el 
PA son dos lípidos que tienen funciones como intermediarios metabólicos y segundos 
mensajeros, por lo que permiten el control integrado del metabolismo con la detección 
de nutrientes y el crecimiento celular.  Ambos lípidos están en el núcleo de rutas 
oncogénicas, pero su contribución al fenotipo maligno no se ha determinado 
completamente. 
Nuestro objetivo fue determinar la contribución de las isoformas DGKα y 
DGKζ a la progresión y mantenimiento del cáncer de mama con el fin de encontrar 
nuevas aproximaciones terapéuticas frente a esta enfermedad.  Hemos encontrado que 
ambas isoformas difieren en su patrón de expresión y funcionalidad.  La expresión de 
DGKα correlaciona inversamente con la activación del eje PI3K-Akt-FoxO, y por lo 
tanto, su expresión es elevada en líneas celulares de mama no transformadas.  Su 
expresión, además, varía a lo largo del desarrollo de la glándula mamaria.  La expresión 
de DGKζ, por el contrario, es más alta en células transformadas. 
Las DGKα y DGKζ promueven la progresión del cáncer de mama a través de 
varios mecanismos.  El consumo de DAG por la DGKζ es necesario para el 
mantenimiento del metabolismo lipídico de los tumores, mediante el control del factor 
de transcripción SREBP-1.  Por su parte, el PA generado por DGK es necesario para 
proporcionar sustratos y mantener señales de fosfotirosina que activan el eje PI3K-Akt-
mTOR.  Sin embargo, aunque la DGKα y DGKζ regulan mTORC1, sólo la DGKα 
modula la activación de Akt y la tirosina quinasa Src. 
La inhibición de DGK reduce el crecimiento tumoral in vitro e in vivo sin 
encender otras rutas de señalización que pueden proporcionar resistencia terapéutica, 
como los ejes de ERK o HIF-1α.  Finalmente, demostramos que la disminución de 
DGKα en células de cáncer de mama altamente maligno impide su crecimiento in vivo, 
ensayado en un modelo de xenotransplante en ratón. 
Nuestros datos otorgan funciones importantes a las isoformas DGKα y DGKζ 
en promover la progresión tumoral, y sugieren que la ruta de DGK puede representar 
una diana efectiva para terapias antitumorales. 
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1. BREAST CANCER 
Breast cancer is the tumor with the highest prevalence among women, and the 
second in frequency worldwide after lung cancer.  Breast cancer incidence increases at a 
rate of 1-2% per year, due to improved diagnostic methods and population aging.  It is 
estimated that 1 of every 8 women will suffer from breast cancer in the coming years. 
1.1. The normal mammary gland 
The normal human mammary gland consists of a branching ductal-lobular system 
that organizes into acini.  The mammary acinus consists of a central layer of luminal 
epithelial cells surrounded by a layer of myoepithelial cells and the basement 
membrane, a specialized laminin-enriched form of extracellular matrix (ECM, (Nelson 
and Bissell, 2006; Weigelt and Bissell, 2008); Figure 1). 
 
	  
Figure 1.  A mammary acinus.  The mammary acinus consists of a layer of luminal epithelial 
cells that form the lumen, surrounded by basal myoepithelial cells.  The acinus lies on a 
specialized form of ECM called the basement membrane. 
 
Unlike other organs, most mammary gland development takes place postnatally, 
during puberty.  In females, a surge of steroid hormones induces the mammary ductal 
rudiment present at birth to undergo a burst of branching morphogenesis (Nelson and 
Bissell, 2006).  There is increasing evidence that, in analogy to the hematopoietic 
compartment, the adult mammary gland has a differentiation hierarchy.  A better 
characterization of the distinct populations would help to identify the so-called cancer-
initiating cells and would contribute to the design of more effective therapies (Stingl 
and Caldas, 2007; Visvader, 2009). 
 
1.2. Breast cancer: classification and clinical implications 
Breast cancer is a complex and heterogeneous disease, traditionally classified based 
on clinical and pathological features to predict outcome and treatment response.  Three 
types of breast tumors can be distinguished immunohistochemically, according to their 
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expression of hormone receptors (HR; estrogen receptor/ER, progesterone receptor/PR) 
and/or the overexpression of the receptor tyrosine kinase (RTK) ERBB2/HER2. 
Although valid, this classification has proved insufficient for predicting clinical 
outcome.  Based on gene expression analysis, recent studies propose a further 
subdivision of some of these groups, leading to a new classification of breast tumors 
that includes six subtypes (Eroles et al., 2011) (Table 1). 
Tumor 
cluster Frequency Characteristics Prognosis Treatment 
Clinical 
equivalent 
Luminal A 50-60% Low mitogenic Good 
Luminal B 10-20% 
Highly 
mitogenic 
Luminal cell 
gene expression 
pattern 
Cytokeratins 8/18 
Intermediate 
Anti-estrogen 
therapy 
HR+ 
(ER+/PR+) 
HER2 10-15% 
Amplification of ERBB2 
amplicon (17q22.24) 
HER2 receptor overexpression 
Low ER expression 
Poor 
Anti-HER2 
antibodies HER2+ 
Basal 10-20% 
Lack of HR expression or 
associated genes 
HER2-negative 
High expression of cytokeratins 
5/6, 17, laminin and fatty acid-
binding protein 7 
Poor 
Normal-
like 
5-10% Basal and adipose cell gene expression pattern Intermediate 
Claudin-
low 
12-14% 
Low expression of cell-cell 
contact genes 
Mesenchymal gene 
overexpression 
High immune cell infiltration 
Poor 
Chemotherapy 
(No targeted 
treatment 
available) 
TN 
(Not 100% 
concordant) 
Table 1.  Breast cancer subtypes according to gene expression analysis.  Gene expression 
analysis distinguishes six types of breast tumors that are indicators of disease prognosis.  The 
table summarizes specific therapies and correlation with the traditional classification.  Modified 
from (Eroles et al., 2011). 
 
Improvement in diagnostic and classification procedures of breast cancer, as well as 
the development of oriented therapies, has contributed to increasing the survival rate of 
patients suffering from this disease.  Resistance to current therapies is an important 
setback for clinicians and patients alike; this resistance can be constitutive (genetic), or 
acquired as a result of treatment.  A better understanding of the molecular mechanisms 
responsible for therapy resistance, as well as the identification of specific targets to treat 
triple-negative (TN) breast cancer, represent an important research area in the field. 
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2.  LIPID METABOLISM IN TUMORS 
Oncogenic alterations lead to chronic, often uncontrolled cell proliferation.  
Emerging evidence suggests that metabolic reprogramming is a prerequisite for the 
rapid proliferation of cancer cells.  This normally involves the consumption of 
additional nutrients and their diversion into macromolecular synthesis pathways. 
 
2.1.  Readjustment of lipid metabolism in tumors 
The first observation regarding metabolic readjustment was that of Warburg in the 
1930s, who described that tumor cells consume glucose through glycolysis (the 
conversion of glucose to pyruvate) at an abnormally high rate, and secrete most of the 
glucose-derived carbon as lactate rather than oxidizing it in the mitochondria in the 
tricarboxylic acid (TCA) cycle.  Further studies established that the glycolytic use of 
glucose provides cancer cells with intermediates necessary for biosynthetic pathways 
that include lipid biosynthesis, needed for continuous generation of membranes in 
rapidly proliferating cells.  In addition, glycolysis can bifurcate into the pentose 
phosphate pathway.  This metabolic shunt generates ribose sugars, required for 
nucleotide synthesis, but also produces NADPH, which is needed for lipid biosynthesis 
and also acts as a reducing agent (DeBerardinis et al., 2008). 
 
2.2.  Lipid biosynthesis 
Untransformed quiescent cells supply their fatty acid (FA) and cholesterol 
requirements from the extracellular environment.  In tumor cells, their uncontrolled 
proliferation forces them to obtain most lipids through de novo synthesis.  During 
proliferation, part of the glycolysis-derived pyruvate is converted to acetyl-CoA that 
enters the TCA cycle, where it is converted into intermediates such as citrate, used in 
lipid biosynthesis.  After importation to the cytosol, citrate is cleaved by the enzyme 
ATP citrate lyase; the resulting acetyl-CoA is used for synthesis of FA and cholesterol 
(Figure 2). 
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Figure 2.  Lipid biosynthesis pathways.  Fatty acid and cholesterol are both synthesized from 
acetyl-CoA.  Acetyl-CoA is generated after cleavage of citrate, a metabolite generated in the 
mitochondria after glucose consumption via glycolysis; the diagram shows the enzymes 
responsible for the distinct steps.  Enzymes highlighted in red are those whose control regulates 
pathway flow. 
 
The activity of lipogenic enzymes is precisely regulated by cell metabolites through 
allosteric mechanisms, posttranslational modifications, and changes in their 
transcription levels.  This guarantees the correct pathway flow and its appropriate 
regulation.  Several of the enzymes implicated in this pathway are overexpressed in 
tumors, and their activity is often increased as a result of oncogenic transformation, 
contributing to the so called “lipogenic phenotype” of cancer (Menendez and Lupu, 
2007). 
 
2.3.  Transcriptional regulation of lipid biosynthesis 
Several enzymes involved in lipid biosynthesis are transcriptionally regulated, as 
stated above.  This regulation is achieved through the sterol-regulatory element binding 
proteins (SREBP), which belong to the basic helix-loop-helix-leucine zipper family of 
transcription factors.  The SREBP are synthesized as immature precursors in the 
endoplasmic reticulum and transported to the Golgi apparatus, where mature, active 
forms are generated by the sequential action of two proteases.  The mature proteins 
enter the nucleus and promote expression of several targets, including SREBP itself 
(Table 2).  Mammals express two SREBP isoforms, SREBP-1 and -2, which regulate 
FA/phospholipid and cholesterol biosynthesis, respectively.  Both SREBP are activated 
downstream of the Akt/mammalian target of rapamycin (mTOR) pathway, providing a 
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direct link between this pathway, frequently mutated in cancer, and the lipogenic 
metabolism of tumors (Krycer et al., 2010). 
SREBP-1 SREBP-2 
SREBP-1 
ATP citrate lyase (ACL) 
Acetyl-CoA carboxylase (ACC) 
Fatty acid synthase (FASN) 
Long chain fatty acid elongase (LFAE) 
Stearoyl-CoA desaturase (SCD) 
SREBP-2 
ATP citrate lyase (ACL) 
Acetocetyl-CoA thiolase (ACT) 
Hydroxymethylglutaryl-CoA synthase (HMGCS) 
Hydroxymethylglutaryl-CoA reductase (HMGCR) 
Mevalonate kinase (MVK) 
Farnesyl pyrophosphate synthase (FPPS) 
Table 2.  SREBP targets.  SREBP transcription factors include two isoforms, SREBP-1 and -2. 
SREBP control the transcription of genes with sterol regulatory elements in the promoter; these 
include genes that encode several enzymes involved in fatty acid (SREBP-1 targets) and 
cholesterol biosynthesis (SREBP-2 targets). 
 
The SREBP pathway is highly conserved in metazoans, where it coordinates lipid 
metabolism with other cell functions, allowing rapid adaptation for survival and growth 
(Osborne and Espenshade, 2009). One feature conserved in SREBP activation is its 
regulation by lipids, which guarantees homeostatic control of lipid synthesis.  SREBP-2 
processing is activated only when cholesterol levels at the endoplasmic reticulum drop 
below a threshold, whereas SREBP-1 responds to changes in oxysterol levels.  Recent 
studies link SREBP-1 activation to phosphatidylcholine (PtdCho) metabolism, such that 
reduction of PtdCho levels and/or the enzymes involved in its synthesis correlate with 
increased levels of active SREBP-1 (Walker et al., 2011).  Other phospholipids can also 
participate, as is the case of phosphatidylethanolamine (PtdEtn) in Drosophilla 
(Dobrosotskaya et al., 2002). 
 
2.4. The role of DAG and PA as metabolic precursors 
Diacylglycerol (DAG) and phosphatidic acid (PA) are two lipids with important 
roles as membrane constituents and as biosynthetic precursors of phospholipids.  In 
addition, they are potent signaling molecules.  DAG and PA thus allow integral control 
of membrane biogenesis and dynamics with nutrient-sensing and cell growth. 
Biosynthetic PA pools are formed mainly by esterification at the C1 and C2 
positions of glycerol-3-phosphate, a derivative of glycolysis intermediates, in a reaction 
that takes place at the endoplasmic reticulum.  PA is an essential intermediate for the 
formation of other phospholipids and is a direct precursor of phosphatidylinositol 
(PtdIns) synthesis.  This process involves PA conversion into the activated DAG form 
CDP-DAG, and the transfer of an inositol molecule (Loewen, 2012; Stace and Ktistakis, 
2006).  Finally, the sequential action of several PtdIns kinases leads to the generation of 
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PtdIns-4,5-bisphosphate (PtdInsP2; Figure 3).  PA stimulates the activity of the PtdIns-
4-phosphate 5-kinase (PIP5K), which catalyzes the last step in PtdInsP2 synthesis, an 
example of the coordination between the metabolic and effector functions of PA (van 
den Bout and Divecha, 2009). 
PA can be dephosphorylated in the ER through the action of the PA 
phosphohydrolase (PAP), which leads to DAG production.  DAG is the precursor of 
PtdCho and PtdEtn, through a reaction that involves choline or ethanolamine transfer 
from their CDP-bound active intermediates to DAG.  In addition, PtdCho and PtdEtn 
precede the synthesis of phosphatidylserine (PtdSer).  DAG can be further esterified in 
the C3 position of the glycerol molecule, leading to production of triglycerides (TAG;	  
(Carrasco and Merida, 2007)), a major constituent of lipid droplet organelles (Figure 3). 
 
Figure 3.  DAG and PA are central metabolites in phospholipid metabolism.  DAG and PA 
are interconverted by DGK and PAP.  PA is the precursor for PtdIns synthesis, which 
terminates in PtdInsP2 generation.  DAG is used to produce PtdCho, PtdEtn and PtdSer.  
Finally, DAG can be esterified into TAG, a form of metabolic energy storage. 
 
In mammalian cells, additional DAG pools are generated in various compartments.  
In the Golgi apparatus, DAG is produced together with sphingomyelin through the 
activity of sphingomyelin synthase, which transforms ceramide and PtdCho in a 
reversible reaction.  At the plasma membrane, receptor stimulation generates DAG, 
which behaves mainly as a second messenger through phospholipase C (PLC)-mediated 
hydrolysis of PtdInsP2.  Finally, DAG conversion into PA through diacylglycerol kinase 
(DGK) action is the first step in PtdInsP2 replenishment, in the so-called “PtdIns cycle”, 
a reaction that also terminates DAG signaling. 
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3.  LIPID-REGULATED PATHWAYS IN CANCER 
Protein binding to some lipids promotes conformational changes that trigger protein 
activation or inhibition in a membrane context.  Signaling lipids control important 
cellular processes including proliferation, apoptosis, metabolism and migration.  These 
lipids, as well as their modifying enzymes and downstream targets, are shared by many 
pathways and constitute a complex network.  Imbalance of lipid-based signaling 
pathways contributes to progression of diseases such as cancer (Wymann and Schneiter, 
2008). 
 
3.1.  The PI3K-Akt axis in breast cancer 
The PtdIns-3-kinases (PI3K) are a family of enzymes that phosphorylate the 
3’-position of the inositol ring of phosphatidylinositols.  They are divided into three 
classes based on structural features and lipid substrate preference.  To date, class I PI3K 
contribution to cancer is the best understood, and will be discussed here. 
Class I PI3K are heterodimers composed of a catalytic and regulatory subunits that 
catalyze PtdInsP2 conversion into PtdIns-3,4,5-trisphosphate (PtdInsP3).  This reaction 
is reversed by the action of the phosphatase and tensin homolog (PTEN), which 
specifically dephosphorylates PtdInsP3 to again produce PtdInsP2 (Bunney and Katan, 
2010; Vanhaesebroeck et al., 2010). 
 
Figure 4.  The PI3K/Akt axis.  PI3K activation leads to PtdInsP2 phosphorylation, which 
generates PtdInsP3.  This reaction is reversed by the PTEN phosphatase.  PtdInsP3 triggers 
PDK1 and Akt translocation to the membrane, where PDK1 phosphorylates and partially 
activates Akt.  Akt phosphorylation by mTORC2 fully activates Akt protein kinase activity.  
Through phosphorylation of several effectors, Akt has a central role in the control of processes 
such as proliferation and metabolism. 
 
PtdInsP3 is almost undetectable in unstimulated cells, and is thus an optimal second 
messenger.  RTK or G protein-coupled receptors trigger PI3K activation by releasing 
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the inhibitory input of the regulatory subunit over the catalytic domain.  PI3K activity is 
further increased by the action of the Ras oncoproteins, leading to the generation and 
transient accumulation of PtdInsP3 at the plasma membrane.  This lipid is recognized by 
proteins that bear a specific lipid-binding module known as the pleckstrin homology 
(PH) domain, which makes them translocate to the plasma membrane (Figure 4). 
The best-characterized PI3K pathway effector is the Ser/Thr kinase Akt (also 
referred to as PKB).  To render Akt fully active, in addition to its PtdInsP3-dependent 
translocation, this protein must be phosphorylated in two sites; the Thr308, mediated by 
phosphoinositide-dependent protein kinase 1 (PDK1), and by the mTOR complex 2 
(mTORC2) in the Ser473.  Active Akt in turn phosphorylates several proteins and 
regulates various biological processes such as cell survival, proliferation, metabolic 
control and angiogenesis (Manning and Cantley, 2007); Figure 4). 
3.1.1.  PI3K/Akt axis alterations in breast cancer 
The PI3K axis is the second most altered pathway in cancer after that of p53.  
Several alterations lead to aberrant activation of this axis in breast cancer (Table 3). 
Alteration Frequency Opportunity for therapeutic intervention 
RTK   
ERBB2 amplification 18-25% Tyrosine kinase inhibitors Monoclonal antibodies 
PI3K   
PIK3CA (p110α) amplification 20-30% 
PIK3CA (p110α) mutations 8.7% 
PIK3CB (p110β) amplification 5% 
PIK3R1 (p85α) mutations Unknown 
Pan-PI3K catalytic inhibitors 
PI3K isoform-specific catalytic inhibitors 
Dual PI3K/mTOR inhibitors 
PTEN   
PTEN protein loss 23-26% 
PTEN mutations 6% No 
PDK1   
PDPK1 amplification 20% Activity inhibitors 
Akt   
Akt1 E17K mutation 4-10% 
Akt2 amplification 3% 
Activity inhibitors 
PH domain-directed inhibitors 
Table 3.  Alterations that lead to aberrant activation of the PI3K/Akt axis in breast cancer 
 
Alterations in PI3K or PTEN tend to be mutually exclusive, and in breast cancer are 
normally associated with tumor type: luminal-like (ER+PR+) tumors normally bear 
mutations in or amplification of the PI3K genes, whereas alterations in PTEN are 
generally found in ER-PR- cancers (Saal et al., 2005).  Both of these alterations can 
coexist with others, e.g., overexpression of the ERBB2 receptor, and provide 
constitutive resistance to some therapies. 
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3.2.  The PA-mTOR axis: an explanation for rapamycin resistance 
mTOR is a Ser/Thr kinase named after the finding that it is the target of the drug 
rapamycin, a macrolid with potent immunosuppressant activity that inhibits mTOR.  
mTOR integrates several intra- and extracellular inputs, such as mitogens, nutrient 
availability or oxygen status; to co-ordinately regulate cell growth and metabolism. 
mTOR associates with various proteins to generate two structurally and 
functionally distinct complexes termed mTORC1 and mTORC2 (Figure 5).  mTORC1 
activates protein and lipid synthesis, nutrient transport and cell cycle progression.  
mTORC2 mediates cytoskeleton remodeling, transcription and metabolism control, and 
promotes cell survival.  These two complexes differ in their response to rapamycin; 
mTORC1 is acutely sensitive to inhibition by rapamycin, whereas mTORC2 can show 
sensitivity after prolonged rapamycin treatment (Guertin and Sabatini, 2007; Laplante 
and Sabatini, 2009).  Mitogenic stimulation of mTOR places this kinase in the 
PI3K/Akt axis, and situates mTOR complexes both down- and upstream of Akt.  This 
pathway is regulated by negative feedback mechanisms that implicate mTORC1-
dependent inhibition of PI3K and mTORC2 (Figure 5). 
 
Figure 5.  The PI3K/Akt/mTOR axis.  mTOR nucleates two complexes of distinct protein 
composition.  mTORC2 phosphorylates and promotes Akt activation.  Akt phosphorylates and 
inhibits the tuberous sclerosis complex (TSC), an upstream inhibitor of mTORC1.  mTORC1 
triggers activation of S6K, a kinase involved in cell growth.  S6K phosphorylates tyrosine 
kinase receptors and Rictor, leading to inhibition of PI3K and mTORC2, respectively.  This 
feedback mechanism guarantees correct activation of the axis. 
 
Mitogenic activation of mTOR requires PA.  At difference from other lipids with 
second messenger functions, PA effectors in general do not appear to have a well-
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defined lipid-recognition module, and use positively charged amino acids that interact 
with the negatively charged monoester headgroup of PA (Shin and Loewen, 2011; Stace 
and Ktistakis, 2006).  mTOR binds PA through its FKBP-rapamycin binding (FRB) 
domain, an interaction that has been structurally characterized by nuclear magnetic 
resonance (NMR) (Veverka et al., 2008).  PA increases mTOR catalytic activity after 
mitogenic stimulation, and stabilizes mTOR complexes (Fang et al., 2001; Toschi et al., 
2009).  The PA-producing enzymes phospholipase D (PLD) and DGK mediate mTOR 
activation (Avila-Flores et al., 2005; Chen et al., 2003; Sun et al., 2008). 
As can be inferred from the above, rapamycin and PA share their mTOR binding 
region.  Since mTOR is the key to control of cell functions, rapamycin semi-synthetic 
analogues (commonly referred as rapalogues, with improved pharmacokinetic 
properties) were candidate drugs for cancer treatment.  Despite the initial promise of 
mTOR inhibition as a broad-spectrum anti-cancer strategy, the clinical performance of 
rapalogues has fallen short of expectations.  Their effect is attributed to the disruption of 
mTORC1-derived negative feedback to PI3K, and to the fact that, in certain types of 
cells, rapamycin poorly inhibits mTORC2, which translates to increased Akt activation 
(Benjamin et al., 2011). 
Tumors can also become refractory to rapalogue treatment by increasing their 
levels of PA, which then competes with the drugs for mTOR binding.  In addition, the 
aggressive types of some tumors such as breast cancer have higher PA levels than their 
less-aggressive counterparts (Chen et al., 2005), and would require higher rapalogue 
doses to inhibit mTOR.  Focus on PA-producing enzymes could thus be an effective 
new approach to mTOR pathway targeting in cancer. 
 
3.3.  PA-mediated regulation of the Ras-ERK axis  
The extracellular signal-regulated kinase (ERK, also termed mitogen-activated 
protein kinase/MAPK) is a major effector of the Ras oncoprotein.  This pathway 
consists of a GTPase-regulated kinase (MAPKKK) that phosphorylates an intermediate 
kinase (MAPKK) that, in turn, phosphorylates and activates an effector kinase (MAPK).  
In the ERK-MAPK pathway, these components are Ras, Raf, MEK and ERK, 
respectively.  Hyperactivation of this axis has been causally linked to acquisition of the 
transformed phenotype. 
The concept that PA regulates the ERK cascade was first proposed by Ghosh and 
coworkers in 1996 (Ghosh et al., 1996).  These authors demonstrated that PA promoted 
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Raf-1 translocation to the plasma membrane, where it interacts with Ras and is 
activated.  PA nonetheless did not stimulate Raf kinase activity (Rizzo et al., 1999; 
Rizzo et al., 2000).  Zhao et al. showed that Ras activation by the guanine exchange 
factor (GEF) Son of sevenless (Sos) is PA-dependent.  They demonstrated that Sos 
interacts with PA with high affinity and specificity via its PH domain, and that this 
interaction is essential for epidermal growth factor (EGF)-induced Sos recruitment and 
Ras activation (Zhao et al., 2007). 
Finally, PA was recently shown to positively modulate the RAB-coupling protein 
(RCP; (Rainero et al., 2012)), which induces motility, invasion and increased survival 
of breast cancer cells; its effects can be mediated by increasing H-Ras and MAPK 
activities (Zhang et al., 2009).  RCP is also implicated in the traffic of adhesion 
receptors, and contributes to integrin-mediated MAPK and PI3K activation in a β-
integrin chain-specific manner (Mills et al., 2009). 
 
3.4.  The PKC-PKD axis in breast cancer 
Protein kinase C (PKC) and protein kinase D (PKD) are important DAG sensors.  
DAG signals are sensed by proteins that contain C1 domains, which are zinc-finger 
domains of approximately 50 amino acids, enriched in cysteine and histidine residues.  
A battery of proteins, including kinases and non-kinases, respond to DAG generation 
(Carrasco and Merida, 2007). 
The PKC are a Ser/Thr kinase family that comprises 2% of the human kinome.  
They are encoded by nine genes, and are subdivided into three groups according to their 
allosteric activation mechanism.  Both classical (cPKC) and novel PKC (nPKC) 
respond to DAG generation, and cPKC to Ca2+ binding as well.  Atypical PKC (aPKC) 
activation is DAG-independent (Rosse et al., 2010). 
The PKC family regulates a wide variety of biological processes, including cell 
proliferation, survival and migration.  Given the large number of isoforms, however, it 
has not been possible to determine function common to all of them.  In addition, PKC 
isozymes have distinct roles depending on cell type (Griner and Kazanietz, 2007).  
Mutations in PKC isozymes are rare in the context of cancer.  PKC deregulation has 
been observed in breast cancer, and several isoforms contribute to its progression, with 
roles as tumor promoters or suppressors, depending on tumor context (Table 4; 
(Urtreger et al., 2012). 
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Isoform Expression Role Mechanism 
Promoter 
Induces multi-drug 
resistance (ER+ tumors) 
Promotes proliferation and 
migration 
PKCα  Increased/ 
decreased 
Suppressor Reduces proliferation 
Promoter Promotes cell growth and angiogenesis PKCβ  Unknown 
Suppressor Reduces protease expression 
Promoter 
Promotes proliferation and 
metastasis; induces anti-
estrogen resistance 
PKCδ  Unknown 
Suppressor Increases apoptosis 
PKCε  Increased Promoter Promotes tumor growth, metastasis 
PKCη  
Increased  
(in ER- breast 
tumors) 
Promoter 
Increases cell survival; 
correlates with lymph node 
status 
PKCθ  Unknown Promoter Promotes cell growth, survival and invasion 
PKCζ  Unknown Promoter Increases proliferative and invasive potential 
PKCι  Increased Promoter Suppresses senescence 
Table 4.  PKC isoforms involved in breast cancer.  Summary of PKC isoforms linked to 
breast cancer progression and the mechanisms implicated in their role as tumor suppressors or 
promoters.  Modified from (Urtreger et al., 2012) 
 
The best-characterized PKC isoforms in breast cancer are cPKCα and nPKCε.  
PKCα levels correlate with ER negativity, and high levels of this isoform predict a poor 
response to anti-estrogen therapy (Assender et al., 2007).  PKCα promotes tumor 
proliferation and migration, although the exact mechanism by which it contributes to 
breast cancer progression remains to be determined (Lonne et al., 2010).  PKCε belongs 
to the nPKC group, and is thought to be regulated both by DAG and PA (Corbalan-
Garcia et al., 2003).  PKCε levels are normally increased in breast tumor samples and 
its expression correlates with tumor aggressiveness, as it promotes proliferation as well 
as invasion (Pan et al., 2005). 
PKD was initially classified as a PKC (PKCµ) because of its DAG dependence, but 
is now considered a separate family.  PKD are both DAG and PKC effectors that 
control cell survival and motility, as well as Golgi vesicle fission and transport, among 
other processes	   (Fu and Rubin, 2011).  To date, three PKD isoforms have been 
identified in human, but only PKD1 is well characterized in breast cancer.  PKD1 levels 
are notably reduced in breast cancer-derived cells as they become more aggressive, as 
confirmed in patient samples; PKD1 also reduces matrix metalloprotease expression, 
and therefore inhibits breast cancer cell invasion	  (Eiseler et al., 2009).  This role is at 
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variance with that described in pancreatic or cervical cancers, for example, in which 
PKD1 has a tumor-promoting function. 
 
3.5.  DAG/PA offers new opportunities for breast cancer treatment 
The previous summary shows how DAG and PA lie directly or indirectly at the 
core of several pathways whose aberrant activation causes or contributes to maintenance 
of the transformed phenotype.  The excessive PtdInsP2 consumption due to oncogenic 
PI3K hyperactivation or to lack of PTEN phosphatase, for instance, places an important 
demand on the cell for continuous PtdIns turnover, a PA-dependent process.  Aberrant 
mTOR activation might also need an enhanced PA supply, and several lines of evidence 
point to a central role for PA in Ras activation.  In addition, the lipogenic metabolism of 
tumors requires continuous phospholipid biosynthesis to generate membranes.  The 
DGK balance DAG and PA levels, and have been implicated in the pathogenesis of 
several diseases.  A closer examination of DGK-mediated functions in cancer would 
help to address the potential of this pathway as a pharmacological target. 
 
4.  DIACYLGLYCEROL KINASES 
The DGK are a family of lipid enzymes that phosphorylate DAG to generate PA.  
DGK activity was first described in rat brain microsomes in the classical studies by 
Hokin and Hokin (1959)	  (Hokin and Hokin, 1959), which led to characterization of the 
PtdIns cycle.  Following those early studies, the DGK were shown to be a large family 
of lipid kinases, present from bacteria to mammals, that are central to the regulation of 
cell responses; they thus offer opportunities for therapeutic intervention in human 
disorders (Figure 6). 
 
Figure 6.  The DGK reaction.  The DGK are enzymes that catalyze transfer of the ATP 
γ-phosphate group to DAG, generating PA. 
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4.1.  Classification 
The DGK species were initially classified according to their enzymological 
properties, based on sensitivity to several activator or inhibitory compounds (Kanoh et 
al., 1990).  To date, the ten known members of the mammalian DGK family are 
classified into five subtypes, based on the distinct regulatory domains in their primary 
sequence (Figure 7); this diversity is further increased by alternative splicing of some 
isoforms (Merida et al., 2008). 
Type Isoforms Structural domains Regulation 
DGKα  
DGKβ  I 
DGKγ   
Ca2+, PtdSer, 
PtdInsP3, Src, Lck, 
PKC 
DGKδ  
DGKη  II 
DGKκ  
 
PKC, 
phospholipids, 
oligomerization 
III DGKε  
 
Phospholipids 
DGKζ  
IV 
DGKι   
PKC, Src, Rb, 
leptin, protein 
interaction 
V DGKθ  
 
PtdSer, PA, RhoA 
Figure 7.  The DGK family.  The DGK family is formed of ten isoforms, classified into five 
subtypes based on domain structure.  This generates a great diversity of DGK that are regulated 
by diverse stimuli.  Modified from (Merida et al., 2008). 
 
4.2.  Structure 
All mammalian DGK share two structural features, a catalytic domain and at least 
two C1 domains; the former is divided into conserved and accessory subdomains.  The 
conserved catalytic domain resembles those of ceramide and sphingosine kinases, 
whereas the accessory subdomain is unique to DGK.  In most cases, these subdomains 
constitute an uninterrupted catalytic domain, except for type II DGK.  The catalytic 
domain has a GGDGXXG motif, similar to the ATP-binding site of protein kinases	  
(Merida et al., 2008). 
The DGK have two C1 domains, except for type V DGKθ, which has three.  
Sequence analysis indicated that with the exception of the first C1 domain of DGKβ 
and DGKγ, the DGK C1 region lacks the key residues that define a canonical C1-like 
phorbol ester-binding domain.  These regions nonetheless contribute to DGK function, 
as mutations within these domains reduce enzyme kinase activity.  Rather than binding 
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DAG, it is likely that the DGK C1 domains act as protein-protein interaction sites; for 
example, they bind to the GPCR adaptors β-arrestins (Nelson et al., 2007).  The DGK 
have other non-conserved structural domains, distinct for each of the five subtypes, that 
appear to have regulatory functions (Merida et al., 2008)	   (Cai et al., 2009)	   (van 
Blitterswijk and Houssa, 2000) (Figure 7). 
 
4.3.  Diacylglycerol kinases functions 
In early studies, the main function attributed to DGK was that of negative 
regulation of PKC signaling.  With the characterization of new DAG receptors and the 
discovery of PA-regulated proteins, our understanding of DGK function has broadened.  
In addition, some DGK functions are independent of their lipid kinase activity, and are 
probably depend on their role as scaffolds. 
DGK regulation of both DAG and PA levels, together with their tissue-specific 
expression pattern and their regulation by a variety of stimuli, makes the study of DGK 
functions extremely complex.  A single DGK isoform might have opposite roles in 
different systems, and/or distinct DGK can have redundant or opposite roles in the same 
system.  Specific DGK isoforms are implicated in many biological processes, and 
mutation or the lack of some isoforms are linked to human diseases (Table 5). 
Subtype Isoform Tissue distribution Function (inferred from knockout mice) 
DGKα  
T cells, brain 
(oligodendrocytes), 
kidney, lung, testis 
Negative regulator of TCR signaling 
Anergy induction I 
DGKβ  Brain (neurons), cardiac muscle Mood disorders 
DGKδ  Ubiquitous (except brain) Insulin resistance II 
DGKη  Ubiquitous Bipolar disorder 
III DGKε  Ubiquitous PtdIns turnover 
DGKζ  Ubiquitous 
Cardiac hypertrophy 
Ischemic response 
Dendritic spine maintenance 
Negative regulator of TCR signaling 
IV 
DGKι  Brain, retina, placenta, ovary 
Neurotransmitter release 
Ras promotion 
Table 5.  Functions attributed to the DGK family.  Most DGK proteins have a tissue-specific 
expression pattern.  Characterization of mice lacking certain isoforms implicates some members 
of this lipid kinase family in the origin of some diseases. 
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4.4.  Diacylglycerol kinases and cancer 
The earliest reports suggesting deregulated DGK activity in transformed cells came 
from studies in the 1980s that showed increased DGK activity in Src- and Erbb-
transformed cells (Kato et al., 1987; Sugimoto et al., 1984), although this was not 
followed by further studies on the DGK contribution to the transformed phenotype. 
The first DGK implicated in cancer was the type IV DGKι.  Mice deficient in this 
isoform developed fewer tumors when on a Ras-dependent background (Regier et al., 
2005).  Despite this initial description, the best-characterized DGK in cancer is the type 
I DGKα.  DGKα is an important effector of hepatocyte growth factor (HGF) and 
vascular endothelial growth factor (VEGF) receptors (Cutrupi et al., 2000) (Baldanzi et 
al., 2004); it is also essential for survival in lymphomas bearing the anaplastic 
lymphoma kinase (ALK; (Bacchiocchi et al., 2005)).  In addition, DGKα contributes to 
the progression of endometrial and hepatic cancer (Filigheddu et al., 2011)	  (Takeishi et 
al., 2012). 
 
4.5.  DGKα  
DGKα was the first mammalian DGK to be isolated and characterized.  It is a 
type I DGK, and thus has N-terminal Ca2+-binding EF hand domains and a recoverin-
like motif, both important in its regulation. 
4.5.1  Transcriptional regulation of the DGKα  gene 
In addition to oligodendrocyte specificity, DGKα expression is particularly 
enriched in the thymus and peripheral T cells.  DGKα is also expressed strongly in 
spleen, lung and testis, whereas its levels are low in liver, kidney and heart.  Initial 
characterization of the DGKα gene provided early insight into the regulatory regions 
that control this tissue-specific expression (Fujikawa et al., 1993). 
Several cDNA microarray analyses also indicate that diverse signaling pathways 
control DGKα gene transcription.  p53 and PPARγ promote DGKα mRNA 
upregulation after treatment with DNA-damaging agents or anti-inflammatory drugs, 
respectively (Kannan et al., 2001; Verrier et al., 2004).  High DGKα levels appear to 
correlate with differentiated or quiescent states (Merida et al., 2009), whereas reduced 
DGKα mRNA levels are described after cell treatment with proliferative stimuli, such 
as IL-2 in CD8+ T cells or FBS in fibroblasts (Gu and Iyer, 2006; Verdeil et al., 2006). 
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Some studies have assessed DGKα expression in cancer.  This isoform is 
upregulated in primary gastric adenocarcinomas and in breast cancer metastases (Hao et 
al., 2004) (Marchet et al., 2007).  An interesting observation was made by (Berrar et al., 
2005), who identified DGKα expression as a good predictor of disease outcome in lung 
adenocarcinoma.  In addition, DGKα is synergistic in mutated p53- and/or Ras-induced 
colon cancer (McMurray et al., 2008), and was identified as a causative gene in 
pancreatic cancer, in which DGKα mutations have been identified (Carter et al., 2010). 
4.5.2.  Regulation of DGKα  activity 
Studies of DGKα activation demonstrated that its membrane translocation is rapid 
and transient, a process that is more sustained for a kinase-defective version of the 
enzyme (Sanjuan et al., 2001).  The N-terminal domain has a negative regulatory role, 
since its deletion led to constitutive DGKα localization at membranes.  An increase in 
Ca2+ levels is nonetheless insufficient to promote DGKα membrane translocation in 
physiological conditions; DGKα must be phosphorylated on tyrosine to be fully active 
(Cipres et al., 2003; Sanjuan et al., 2001).  Tyrosine 335, a residue that lies at the hinge 
between the C1 domain and the catalytic region, was identified as a major DGKα 
phosphorylation site and proved critical for its translocation to the membrane.  
Phosphorylation of this residue is mediated by tyrosine kinases of the Src non-receptor 
tyrosine kinase family (SFK; (Cutrupi et al., 2000), which phosphorylate DGKα in 
response to growth factors such as HGF (Baldanzi et al., 2008; Baldanzi et al., 2004).   
In T cells, the tyrosine kinase Lck, which is activated downstream of the T cell receptor 
(TCR), phosphorylates DGKα at Tyr335 (Merino et al., 2008).  These data led to the 
proposal of an activation model for DGKα, in which Ca2+ elevation induces a 
conformational change that releases the negative regulation of the DGKα N-terminal 
domain.  Tyrosine phosphorylation induces an active, open conformation that stimulates 
DGKα translocation to the membrane, where it phosphorylates DAG.  In addition to 
dephosphorylation, PA production restores the closed, inactive conformation of DGKα 
and promotes its return to the cytosol. 
4.5.3.  DGKα  functions 
The functions initially attributed to DGKα were negative regulation of Ras 
activation in T cells through modulation of membrane binding, and activation of the Ras 
GEF Ras guanyl-releasing protein 1 (RasGRP1;	  (Sanjuan et al., 2003)).  This idea was 
further reinforced by the hyperactive phenotype of T cells from DGKα-deficient mice	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(Olenchock et al., 2006).  Whereas DGKα functions in the immune system are related 
mainly to its role as a negative regulator of DAG signaling, several studies suggest that 
DGKα-produced PA is important for the survival, migration and invasive properties of 
tumors (Table 6). 
 
Stimulus Mediators Effect References 
HGF 
Rac 
aPKC 
RhoGDI 
Migration (Chianale et al., 2010) 
VEGF - Angiogenesis Cell proliferation 
(Baldanzi et al., 
2004) 
NPM-ALK - Anaplastic large-cell lymphoma survival 
(Bacchiocchi et al., 
2005) 
TNFα  PKCζ/NFκB Melanoma survival (Kai et al., 2009; 
Yanagisawa et al., 
2007) 
17-β-estradiol GRP30 
Endometrial cancer 
proliferation, motility, 
survival 
(Filigheddu et al., 
2011) 
Integrin RCP Invasive migration (Rainero et al., 2012) 
Table 6.  Downstream effectors of DGKα-generated PA.  Through its function as a PA 
producer, DGKα controls several pathways, most of which promote cell proliferation, survival 
and motility, and contribute to cancer progression. 
 
4.6.  DGKζ  
DGKζ is one of the two type IV DGK, and is thus characterized by a MARCKS 
motif that overlaps with a nuclear localization sequence (NLS).  DGKζ also has four C-
terminal ankyrin repeats and a PDZ-binding domain, which allow the enzyme to interact 
with several proteins (Topham et al., 1998)	  (Rincon et al., 2007). 
4.6.1.  DGKζ  expression 
DGKζ was initially cloned from endothelial cells, rat brain and retina.  Although it 
is a ubiquitous enzyme, its mRNA is expressed strongly in thymus, brain and skeletal 
muscle.  Two alternatively spliced isoforms have been identified, which originate 
distinct proteins of 115 and 130 kDa; the latter has only been identified in skeletal 
muscle (Rincon et al., 2012). 
4.6.2.  Regulation of DGKζ  activity and subcellular localization 
DGKζ has a MARCKS motif, as mentioned above, that includes consensus PKC 
phosphorylation sites.  Its phosphorylation by PKC, as well as its ability to form various 
complexes, modulates both DGKζ localization and activity (Cai et al., 2009) (Rincon et 
al., 2012). 
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Early studies in adherent cells identified DGKζ as a nuclear enzyme whose 
localization correlates with cell cycle phase.  PKC-mediated phosphorylation of the 
DGKζ NLS was proposed to negatively regulate its nuclear localization (Topham et al., 
1998).  Nuclear DGKζ function has not been fully elucidated; it is thought to bind the 
retinoblastoma (Rb) protein, which increases its activity and downregulates cyclin D3 
levels (Evangelisti et al., 2009; Los et al., 2007).  In T cells, PKC-dependent 
phosphorylation of the MARCKS domain is necessary for DGKζ membrane 
translocation (Santos et al., 2002).  In its C-terminal half, DGKζ also has an ERK 
phosphorylation consensus sequence	  (Avila-Flores et al., 2005), whose function remains 
unknown. 
4.6.3.  DGKζ  functions 
The extreme versatility of DGKζ is underlined by recent studies.  This isoform 
clearly has a dual role, as it inhibits DAG-regulated enzymes and activates PA-mediated 
functions (Rincon et al., 2012).  DGKζ acts a negative regulator of PKCα signal 
duration; the two proteins interact in a complex such that PKCα maintains DGKζ in a 
non-phosphorylated active form, allowing mutual regulation	   (Luo et al., 2003a, b).  
DGKζ-produced PA modulates several signaling effectors, one of which is PIP5K, an 
enzyme that catalyzes the final step of PtdInsP2 synthesis (Luo et al., 2004).  DGKζ also 
regulates Rac1, a Rho GTPase family member that regulates changes in the actin 
cytoskeleton via activation of p21-activated kinase 1 (PAK1; (Abramovici et al., 2009)).  
Another DGKζ effector is mTOR, a master integrator of signals and controller of cell 
growth	  (Avila-Flores et al., 2005). 
DGKζ  is strongly expressed in thymus and mature T cells, where it appears to 
have redundant functions with DGKα as a negative regulator of the 
DAG/RasGRP1/Ras axis.  In DGKζ-deficient mice, the Ras/ERK pathway is 
hyperactive	  (Zhong et al., 2003).  Despite this apparent redundancy, the contribution of 
both isoforms to DAG-regulated functions in T lymphocytes seems to differ; for 
instance, recent experiments showed that DGKζ is the main isoform responsible for 
DAG metabolism at the immune synapse	  (Gharbi et al., 2011). 
Through several mechanisms, DGKζ can thus participate in various biological 
processes, including cardiac remodeling, neuron function, T cell response and innate 
immunity (Rincon et al., 2012) 
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Diacylglycerol kinases (DGK) balance the levels of diacylglycerol and 
phosphatidic acid (PA), two lipids that lie at the core of several metabolic and signaling 
pathways involved in breast cancer progression.  While various studies implicate 
DGKα-generated PA in several cancer processes, there are no data for DGKζ.  The 
redundancy between these two isoforms makes it necessary to address the possible 
DGKζ contribution to the maintenance of breast cancer.  Our overall objective is to 
characterize the implication of the DGK pathway in breast cancer 
physiopathology. 
 
To achieve this aim, we propose the following specific objectives: 
 
1. Determine and compare DGKα and DGKζ expression and activity in breast 
cancer and the normal mammary gland, and correlate them with those of their 
regulators. 
 
2. Assess the contribution of DGKα and DGKζ to breast cancer progression. 
2.1 Evaluate DGK-mediated control of the SREBP (sterol regulatory 
element-binding proteins) pathway in breast cancer. 
2.2 Examine the contribution of the DGK pathway to the maintenance of the 
oncogenic axes that promote breast cancer progression 
(PI3K/Akt/mTOR, Ras/ERK, ERBB2/Src). 
2.3 Examine the contribution of the DAG/PA axis to the development of 
pharmacological resistance in breast cancer cells. 
 
3. Study the relevance of DGK expression and activity for breast cancer initiation 
and progression in vivo. 
 
4. Establish a reference framework to evaluate the potential of the DGK pathway 
as a target for therapeutic intervention. 
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1.  Cell lines 
The MCF-10A, MCF-7 and MDA-MB-231 cell lines were purchased from the 
ATCC.  The cell lines MDA-MB-468, T-47D and Hs 578T were kindly donated by Dr. 
Lourdes Planelles (CNB/CSIC, Madrid), BT-474 by Dr. Santos Mañes (CNB/CSIC, 
Madrid), SK-BR-3 by Dr. Javier Benítez (CNIO, Madrid).  The normal luminal cell line 
HB4a was kindly donated by Dr. Hugh T. Reyburn (CNB/CSIC).  A summary of the 
characteristics of the breast-derived cell lines as well as their culture conditions are 
detailed in Table 7.  All cell lines were maintained at 37ºC and 5% CO2, except those 
cultured in Leibovitz’s L15, where CO2 was absent. 
 
2.  Antibodies 
Antibody Supplier Antibody Supplier 
Goat anti-mouse HRP Dako Anti-pAkt Ser473 Cell Signaling 
Goat anti-rabbit HRP Dako Anti-pAktThr308 Cell Signaling 
Anti-DGKα Abnova Anti-Akt Cell Signaling 
Anti-DGKζ Donated by MK Topham Anti-mTOR Cell Signaling 
Anti-tubulin Sigma Anti-Rictor Bethyl Laboratories 
Anti-FoxO3a Cell Signaling Anti-Raptor Cell Signaling 
Anti-FoxO1 Cell Signaling Anti-GAPDH Santa Cruz Biotechnology 
Anti-pFOXO1/3a 
Thr24/Thr32 Cell Signaling Anti-PARP Cell Signaling 
Anti-β-actin Sigma Anti-pSrc Tyr416 Cell Signaling 
Anti-HER2 Cell Signaling Anti-Src Cell Signaling 
Anti-phospho Tyr 
(4G10) Upstate 
Anti-pERK 
Tyr202/Thr204 Cell Signaling 
Anti-pSer PKC 
substrates Cell Signaling Anti-ERK Cell Signaling 
Anti-pPanPKC 
(γThr514) Cell Signaling Anti-HIF1α BD Biosciences 
Anti-pPanPKC 
(βSer660) Cell Signaling Anti-ILK BD Biosciences 
Anti-PKCα (C-20) Santa Cruz Biotechnology Anti-GM130 BD Biosciences 
Anti-pPKD Ser744/8 Cell Signaling Anti-CD49f-AF488 Beckman Coulter 
Anti-PKD Santa Cruz Biotechnology Anti-CD49b-PE Beckman Coulter 
Anti-SREBP1 Millipore Anti-Sca1-PECy7 Beckman Coulter 
Anti-pP70S6K Thr389 Cell Signaling Anti-CD45-biotin Beckman Coulter 
Anti-P70S6K Cell Signaling Anti-CD31-biotin Beckman Coulter 
Anti-rpS6 Ser240/4 Cell Signaling Anti-Ter119-biotin Beckman Coulter 
Anti-rpS6 Cell Signaling Anti-BP1-biotin Beckman Coulter 
Anti-cyclin D3 Cell Signaling Streptavidin APC-Cy7 Beckman Coulter 
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3.  Reagents 
Reagent Supplier Reagent Supplier 
Leupeptin Roche Dioctanoyl-DAG Avanti Polar Lipids 
Aprotinin Roche Dioleoyl-DAG Avanti Polar Lipids 
Triton X-100 Calbiochem Dioctanoyl-PA Avanti Polar Lipids 
CHAPS Calbiochem Dioleoyl-PA Avanti Polar Lipids 
R59949 Calbiochem Brain PtdSer Avanti Polar Lipids 
Bisindolylmaleimide Calbiochem Liver PtdIns Avanti Polar Lipids 
Gö6976 Calbiochem Brain PtdIns-4-P Avanti Polar Lipids 
Rapamycin LC Laboratories [γ-32P]ATP Hartmann Analytic 
 
Remaining reagents where purchased from Sigma, or as indicated.  HPLC-grade 
solvents for lipid handling were acquired from Merck. 
4.  Western blot analysis 
For western blot analysis, cells were lysed (4ºC, 15 min) in p70 buffer (10 mM 
Hepes pH 7.5, 15 mM KCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol and 0.2% 
NP-40) containing protease and phosphatase inhibitors (20 µM leupeptin, 1.5 µM 
aprotinin, 1 mM PMSF, 1 mM sodium orthovanadate, 40 mM β-glycerophosphate and 
2 mM NaF).  The lysate was then centrifuged (12000 xg, 15 min, 4ºC) and the 
supernatant was quantified with the Pierce 660 nm Protein Assay (Thermo Scientific).  
Samples were denatured in Laemmli buffer (Laemmli, 1970) and resolved by SDS-
polyacrylamide gel electrophoresis (PAGE).  Proteins were transferred to 
polyvinylidene fluoride (PVDF) membranes (Bio-Rad) and incubated with appropriate 
antibodies. 
 
5.  Fractionation analysis 
5.1.  Membrane isolation 
To purify cell membranes, cells were lysed in 50 mM Tris-HCl pH 7.5, with 
protease and phosphatase inhibitors.  Lysates were centrifuged (800 xg, 15 min, 4ºC) to 
exclude nuclei and cell debris, and the remaining supernatant was further centrifuged 
(100000 xg, 1 h, 4ºC).  The pellet, corresponding to the membrane fraction, was 
resuspended in 50 mM Tris-HCl pH 7.5 and used for activity assays. 
 5.2.  Preparation of nuclear extracts 
Nuclear extracts were obtained as described (Meyer et al., 2002).  Cells were 
resuspended in TKM buffer (25 mM Tris-HCl pH 7.5, 5 mM KCl, 1 mM MgCl2) and 
incubated (5 min, 4ºC) prior to addition of 1 vol TKM buffer containing 1% NP-40, 
followed by further incubation (5 min, 4ºC).  Nuclei were sedimented (1000 xg, 5 min, 
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4ºC), and resuspended in TKM buffer containing 0,5% NP-40 and 100 mM NaCl.  
Nuclei were separated from inner membranes by centrifugation (2100 xg, 5 min) 
through a 3-volume cushion of 1.62 M sucrose in TKM buffer.  The pelleted nuclei 
were washed with TKM buffer containing 0.5% NP-40 and 100 mM NaCl, and lysed in 
high salt RIPA buffer (20 mM Tris-HCl pH 7.5, 300 mM NaCl, 2 mM EDTA, 
1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate and 10% glycerol).  All 
buffers contained protease and phosphatase inhibitors. 
 
6.  Immunoprecipitation 
For protein-protein interaction analysis by immunoprecipitation, cells were lysed 
(30 min, 4ºC) in 50 mM Hepes pH 7.4, 150 mM NaCl, 1% NP-40 and 10% glycerol, 
containing protease and phosphatase inhibitors.  Lysates (500 µg - 1 mg) were 
incubated (overnight, 4ºC) with the appropriate antibody, followed by incubation with 
50 µl of 50% protein G-Sepharose slurry (1 h, 4ºC).  Immunoprecipitates were washed 
thrice in lysis buffer and once with 0.5M LiCl.  Immunoprecipitated proteins were 
resolved by SDS-PAGE and transferred to PVDF membranes for Western blot analysis. 
When phosphotyrosine was immunoprecipitated, Triton X-100 was used instead of 
NP-40 and incubation time with antibody was reduced (3 h).  Immunoprecipitated 
complexes were washed twice each with lysis buffer, washing buffer 1 (100 mM Hepes 
pH 7.0, 250 mM LiCl), washing buffer 2 (10 mM Hepes pH 7.0, 100 mM NaCl, 1 mM 
EDTA), and 10 mM Hepes pH 7.0.  The resulting immunoprecipitates were used for 
Western blot analysis or activity assay, as described below. 
6.1.  mTOR immunoprecipitation 
To detect mTOR complexes, immunoprecipitation was performed as described 
(Kim et al., 2002).  Cells were lysed in 40 mM Hepes pH 7.5, 120 mM NaCl, 1 mM 
EDTA, 0.3% CHAPS, containing protease and phosphatase inhibitors.  Lysates 
(500 µg) were incubated with anti-mTOR antibody (Cell Signaling, 1:100, overnight, 
4ºC), followed by incubation with 50 µl of 50% protein G-Sepharose slurry (1 h, 4ºC).  
Immunoprecipitates were washed four times with lysis buffers and twice with 50 mM 
Hepes pH 7.5, 150 mM NaCl.  Immunoprecipitated proteins were resolved by SDS-
PAGE and transferred to PVDF membranes for Western blot analysis. 
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7.  Plasmids, RNAi sequences and transfections 
The following plasmids were used in the present study: 
Plasmid Reference/Supplier 
pSUPER.retro-shRNA mouseDGKα (control) A. Ávila-Flores 
pSUPER.retro-shRNA humanDGKα A. Ávila-Flores 
pSUPER.retro-shRNA humanDGKζ A. Ávila-Flores 
pEFbosEGFP-C1bPKCθ (Carrasco and Merida, 2004) 
GFP-PH-CERT Sima Lev; (Peretti et al., 2008) 
pLKO-Tet-on-neo (Wiederschain et al., 2009)/Addgene (#21916) 
pRSV-Rev John Stingl (CRI, Cambridge, UK) 
pMDLg/pRRE John Stingl (CRI, Cambridge, UK) 
pVSVG John Stingl (CRI, Cambridge, UK) 
 
Plasmids were transfected with Lipofectamine LTX according to manufacturer’s 
instructions.  Assays were performed 48 h post-transfection.  DGK-targeting RNAi 
oligonucleotides have been described (Avila-Flores et al., 2005)	   (Rincon et al., 2007) 
(Gharbi et al., 2011)  and were transfected with Oligofectamine as recommended by the 
manufacturer.  Effective DGK depletion was achieved at 72 h after transfection. 
 
8.  Establishment of Tet-on inducible cell lines MDA-MB-231-shRNA-
control, -shRNA-DGKα , and -shRNA-DGKζ  
DGK-targeting RNA sequences, detailed below, were cloned between the AgeI and 
EcoRI restriction sites of the pLKO-Tet-on-neo vector.  Incorporation of the insert was 
verified after digestion with XhoI.  Clones that contain the shRNA oligos yield two 
closely migrating bands at and below 200 bp.  In addition, the presence of the insert was 
confirmed by sequencing using a primer (shRNASeq) that anneals upstream of the 
H1/TO promoter.  Inducible insert expression was achieved by treating the cells with 
doxycyline (100 ng/mL, every 48 h).  DGK reduction was effective after 96 h of 
doxycycline treatment.  The oligonucleotides designed were as follows: 
Oligonucleotide Sequence 
shRNA-mouse DGKAlpha sense  
5’ CCG GAC ACA AGA CCA CAG ATG ATA 
ACT CGA GTT ATC ATC TGT GGT CTT GTG 
TTT TTT 3’  
shRNA-mouse DGKAlpha antisense 
5’ AAT TAA AAA ACA CAA GAC CAC AGA 
TGA TAA CTC GAG TTA TCA TCT GTG GTC 
TTG TGT 3’ 
shRNA-mouse DGKZeta sense 
5’ CCG GCT ATG TGA CGG AGA TTG CCA 
ACT CGA GTT GGC AAT CTC CGT CAC ATA 
GTT TTT 3’ 
shRNA-mouse DGKZeta antisense 
5’ AAT TAA AAA CTA TGT GAC GGA GAT 
TGC CAA CTC GAG TTG GCA ATC TCC GTC 
ACA TAG 3’ 
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shRNA-human DGKAlpha sense 
5’ CCG GGC CAG AAG ACC ATG GAT GAA 
ACT CGA GTT TCA TCC ATG GTC TTC TGG 
CTT TTT 3’ 
shRNA-human DGKAlpha antisense 
5’ AAT TAA AAA GCC AGA AGA CCA TGG 
ATG AAA CTC GAG TTT CAT CCA TGG TCT 
TCT GGC 3’ 
shRNA-human DGKZeta sense 
5’ CCG GCT ATG TGA CTG AGA TCG CAA 
ACT CGA GTT TGC GAT CTC AGT CAC ATA 
GTT TTT 3’ 
shRNA-human DGKZeta antisense 
5’ AAT TAA AAA CTA TGT GAC TGA GAT 
CGC AAA CTC GAG TTT GCG ATC TCA GTC 
ACA TAG 3’ 
shRNASeq primer 5’ GGC AGG GAT ATT CAC CAT TAT CGT TTC AGA 3’ 
 
9.  Generation of viral particles and transduction 
HEK293T cells were transfected with the appropriate retro- or lentiviral vector 
through DNA coprecipitation with calcium phosphate ((Ca3(PO4)2) and the appropriate 
viral envelopes.  DNA was used at a proportion of 2.5 µg/106 packaging cells, which 
were grown in 10 cm2 plates.  After 16 h of transfection, cell medium was replaced by 
that of the transduced cells and incubated for 24 h, after which the medium containing 
the viral particles was collected and centrifuged (1500 xg, 5 min, 4ºC).  The remaining 
supernatant was filtered through a low-protein binding 45 µm filter and added to the 
cells at a 1:1 ratio with normal growth medium.  Selection was started 48 h after 
infection (G418, 400 µg/mL, 7 days).  MDA-MB-231-shRNA-control, -shRNA-DGKα, 
and -shRNA-DGKζ cell lines were derived from parental MDA-MB-231 by infecting 
the pSUPER.retro version of the indicated shRNA sequences.  Establishment of stable 
and inducible MDA-MB-231-derived cell lines for DGK knockdown was achieved by 
infecting the pLKO-Tet-on-neo with the corresponding shRNA sequences. 
 
10.  Lipid kinase activity assays 
10.1.  DGK assay 
DGK activity was measured using 1,2-dioctanoyl (C8)- or 1,2-dioleoyl (C18:1)-
DAG as the substrate.  To measure total kinase activity, cells were lysed by sonication 
in 50 mM Tris-HCl pH 7.5, with protease and phosphatase inhibitors.  Cell lysates were 
centrifuged (12000 xg, 15 min, 4ºC).  Whole cell extract supernatant (20 µg), membrane 
fraction or phosphotyrosine immunoprecipitates (obtained as described above) were 
mixed with lipid micelles containing the substrate. 
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Lipid micelles were prepared by sonication of the lipid in 50 mM Tris-HCl pH 7.5 
(10 min, room temperature).  The final concentration of both lipids in the assay was 
0.5 mM (C8-DAG) and 2 mM (C18:1-DAG).  When C18:1-DAG was the substrate, 
PtdSer was included in the micelles at the same molar ratio.  The reaction was initiated 
by addition of reaction mix (1 mM ATP, 10 mM MgCl2, 100 mM NaCl, 1 mM DTT 
and 10 µCi [γ-32P]-ATP) and incubated (10 min, 25ºC) in a final volume of 50 µL.  The 
reaction was terminated by addition of 1 N HCl.  Lipids were extracted after addition of 
CHCl3/MeOH (2:1, v/v).  The organic layer was recovered, dried and applied to silica 
gel TLC plates (Whatman), which were developed in a CHCl3/MeOH/4 M NH4OH 
solvent system (9:7:2, v/v/v), dried, and autoradiographed.  A non-radioactive standard 
of the reaction product was used to identify the lipid of interest. 
10.2.  PI3K assay 
PI3K activity was measured in phosphotyrosine immunoprecipitates, obtained as 
described above, using PtdIns as substrate.  PtdIns-containing micelles were prepared 
by sonication of the lipid in 10 mM Hepes pH 7.0 (5 min, room temperature).  The final 
concentration of the lipid in the assay was 0.2 mM.  The reaction was initiated by 
addition of reaction mix (20 µM ATP, 10 mM MgCl2 and 10 µCi [γ-32P]-ATP) and 
incubated (30 min, 25ºC) in a final volume of 50 µL.  The reaction was terminated by 
addition of 1 N HCl.  Lipids were extracted after addition of CHCl3/MeOH (1:1, v/v).  
The organic layer was recovered, dried and applied to silica gel TLC plates (Whatman), 
which were developed in a CHCl3/MeOH/4 M NH4OH solvent system (9:7:2, v/v/v), 
dried, and autoradiographed.  A non-radioactive standard of the reaction product was 
used to identify the lipid of interest. 
 
11.  Cell lipid extraction 
Cell lipids were extracted by a modification of the method of Bligh and Dyer (Bligh 
and Dyer, 1959).  Prior to extraction, an aliquot was stored for protein determination.  
Briefly, cells were rinsed thrice in cold PBS and resuspended in 1 mL of PBS; 4 mL of 
CHCl3/MeOH/12 N HCl (50:100:1, v/v/v) were then added, and organic and aqueous 
phases separated by centrifugation (1500 xg, 10 min).  The upper aqueous phase was 
further washed with CHCl3.  The recovered organic phases containing the lipids were 
mixed and dried under a nitrogen stream. 
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12.  DAG level measurement 
DAG levels were measured as described (Preiss et al., 1986).  Dried lipids were 
solubilized in 20 µL of a 7.5% octyl-β-D-glucopiranoside and 25 mM 
dioleoylphosphatidylglycerol solution, sonicated (15 sec, room temperature) and 
incubated (10 min, room temperature).  Resuspended lipids were then mixed with 70 µL 
of reaction mix (50 mM imidazole-HCl pH 6.6, 50 mM LiCl, 12.5 mM MgCl2, 1 mM 
EGTA, 2 mM DTT and 5 µg purified Escherichia coli DGK).  The reaction was 
initiated by addition of [γ-32P]-ATP (20 µCi) and allowed to proceed for 30 min.  The 
reaction was terminated by addition of 1 N HCl.  Lipids were extracted after addition of 
CHCl3/MeOH (2:1, v/v).  The organic layer was recovered, dried and applied to silica 
gel TLC plates, which were developed in a CHCl3/acetone/MeOH/AcOH/H2O solvent 
system (10:4:3:2:1, v/v/v/v/v), dried, and autoradiographed.  Data were normalized by 
expressing the degree of DAG radiolabeling (phosphorimager pixels) per nmol of 
phospholipid phosphate. 
Phospholid-associated phosphate was determined as described (Flores et al., 1996).  
Briefly, dried lipids were hydrolyzed in 70% perchloric acid (30 min, 180ºC).  Samples 
were cooled and mixed with ammonium molybdate (3 mM final concentration) and 
ascorbic acid (72 mM final concentration), after which they were incubated (15 min, 
56ºC), and absorbance measured at 690 nm. 
 
13.  In vivo radiolabeling of phospholipids 
This assay was performed in collaboration with Dr. David Jones (Paterson Institute 
for Cancer Research, University of Manchester, Manchester, UK).  MDA-MB-231 cells 
were seeded in 6-well plates.  After 24 h, they were treated with DMSO, R59949, 
rapamycin or R59949 plus rapamycin for a further 24 h, washed three times with 
phosphate- and serum-free DMEM before reincubating with phosphate- and serum-free 
DMEM containing 300µCi/mL 32P-orthophosphate and drugs for 1 h.  Thereafter, cell 
lipids were extracted as described above.  The recovered organic phase containing the 
lipids was dried under nitrogen.  Of the total lipid extract, 20% was analyzed by TLC to 
determine PtdIns-4-phosphate and PtdInsP2 radiolabeling.  The remainder, 80%, was 
used to calculate the total phospholipid mass (as nmoles of phospholipid phosphate).  
Data were normalized by expressing the degree of PtdIns-4-phosphate and PtdInsP2 
radiolabeling (phosphorimager pixels) per nmol of phospholipid phosphate.  HPLC was 
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used to verify the PtdIns-4-phosphate and PtdInsP2 radiolabeling data using a 
previously published method (Jones et al., 1999). 
 
14.  Cell cycle protocol and analysis by flow cytometry 
Cells were seeded at a confluence of 5 x 103 cells/cm2, incubated 24 h, and then 
synchronized by serum starvation for 20 h.  After this treatment, approximately 75% of 
the population was in G0-G1.  Cell cycle entrance was induced by addition of FBS to a 
final concentration of 10%.  Indicated drugs or vehicle were added 8 h before serum 
addition.  At different points, cells were washed in PBS and trypsinized.  
Approximately 106 cells were analyzed by propidium iodide staining in an Epics XL-
MCL (Beckman Coulter) cell sorter for cell cycle phase distribution.  Cell cycle phases 
were adjusted with WinCycle software (Phoenix Flow Systems). 
 
15.  Analysis of apoptosis by flow cytometry 
Cells (104 cells/cm2) were seeded in 10-cm dishes, and after 24 h were serum-
deprived.  Drugs were then added at the indicated concentrations for 24 h.  Cells were 
collected and stained with annexin V-FITC (Apoptosis Detection Kit I, BD 
Pharmingen) according to manufacturer’s instructions.  Propidium iodide (100 µg/mL) 
was added prior to cell sorting.  The cell death profile was analyzed by flow cytometry 
in an in an Epics XL-MCL cell sorter. 
 
16.  Colony formation assays 
Cells (5 x 102/well) were seeded in 12-well plates; after 48 h, drugs were added at 
indicated concentrations every 48 h for 7 days.  Colonies and foci were stained with 
0.1% crystal violet solution in 20% methanol.  After extensive washing, crystal violet 
was dissolved in 10% acetic acid, and absorbance measured at 620 nm. 
 
17.  3D cultures 
MDA-MB-231 cells were cultured in a 3D matrix of collagen and laminin (Matrigel, 
BD Biosciences) as described (Debnath et al., 2003).  Briefly, 50-60 µL Matrigel were 
added to each well of an 8-well chamber (1 cm2 surface) and allowed to solidify 
(20 min, 37ºC).  Cells were trypsinized and resuspended in assay medium (DMEM, 
5% FBS, 2 mM L-Gln and 2.5% Matrigel); 1.5 x 103 cells/cm2 were seeded.  Assay 
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medium was changed every 48 h, and cells allowed to grow for 14 days.  For RNA 
extraction, cells were seeded on 10 cm2-plates and Matrigel culture resuspended directly 
into Trizol reagent. 
 
18.  Immunofluorescence 
For immunofluorescence, cells were plated on gelatin-coated slides and, after the 
indicated treatments, were fixed in 4% paraformaldehyde (10 min, room temperature).  
The cells were permeabilized with 0.3% Triton X-100 (10 min) and blocked with 10% 
goat serum in TBS (30 min, room temperature).  For GM130 staining, cells were 
permeabilized with 0.5% saponin.  Cells were incubated with the appropriate primary 
antibody in incubation buffer (1% goat serum in TBS; 1 h, 37ºC or overnight, 4ºC) in a 
humidified chamber.  Secondary antibodies were added to samples and incubated (1 h, 
room temperature).  Finally, samples were incubated with DAPI or rhodamine-
phalloidin (1:1000, 10 min, room temperature) and mounted with Aqua Poly/Mount 
(Polysciences).  Cells were visualized under a Leica TCS SP5 confocal or a Leica 
DMI6000B fluorescence microscope. 
 
19.  Immunohistochemistry 
Tissue sections were formalin-fixed and paraffin-embedded.  Sections were 
prepared for antibody staining as described (Carracedo et al., 2008).  Briefly, following 
deparaffinization and hydration, antigen retrieval was performed in 12.5 mM sodium 
citrate pH 6.0 (30 min, 90ºC).  Tissue sections were washed in TBSt (TBS, 
0.1% Tween-20) and blocked with 10% goat serum (1 h, room temperature).  Primary 
antibody was incubated (overnight, 4ºC), followed by incubation with HRP-coupled 
secondary antibody (Dako, 1:200, 2 h, room temperature).  Staining was detected with 
the DAB Peroxidase Substrate Kit (Vector Laboratories), and slides were counterstained 
with hematoxylin (Fisher Scientific) and mounted in Permount (EMS). 
 
20.  Cell sorting isolation of murine mammary gland subpopulations 
The third and fourth mammary glands were remove from virgin female mice aged 8 
to 25 weeks, after which they were dissociated (16 h, 37ºC) in DMEM/F12 (1:1, v/v) 
containing collagenase/hyalurodinase (Stem Cell Technologies).  A single mammary 
cell suspension was obtained after sequential treatment with 0.25% trypsin and 
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dispase/DNase solution (2 min, room temperature), followed by filtration through a 
40 µm cell strainer.  The remaining cells were resuspended to a final concentration of 
107 cells/mL and stained for fluorescence-activated cell sorting (FACS). 
For FACS staining, cells were pre-blocked in 10% normal rat serum (10 min, 4ºC) 
and washed.  Cells were then stained (10 min, 4ºC) with the following surface markers: 
CD49f-AF488, CD49b-PE, EpCAM-AF647, Sca1-PECy7 CD45-biotin, CD31-biotin, 
Ter119-biotin and BP1-biotin.  Biotin-coupled antibodies, which bind to non-epithelial 
lineages, were detected with streptavidin APC-Cy7.  Cells were finally stained with 
DAPI.  Mammary epithelial subpopulations were sorted as indicated. 
Marker Cell type CD49f EpCAM CD49b Sca-1 
Basal High Low   
Luminal Medium High   
Non-clonogenic   - + 
Double positive progenitor   + + 
Alveolar progenitor   + - 
 
RNA from sorted populations was extracted with the PicoPure RNA Isolation kit 
(MDS Analytical Technologies) according to the manufacturer’s protocol, and used for 
qPCR analysis as described below. 
 
21.  RT-PCR 
cDNA was synthesized from cell culture-extracted RNA (1 µg) after treatment with 
DNase (Invitrogen), and retrotranscribed with Oligo dT (Invitrogen) and the 
SuperScript II Reverse Transcriptase (Invitrogen) according to manufacturer’s 
indications in a final volume of 20 µL. 
PCR reactions were performed with 2 µL cDNA and appropriate primers.  PCR 
conditions were: 95ºC for 2 min, 30 cycles at 95ºC for 30 s, 60ºC for 30 s and 72ºC for 
1 min, and a final extension of 72ºC for 8 min.  PCR products were resolved by 1.5% 
agarose gel electrophoresis, stained with ethidium bromide and documented with the 
GelDoc system (Bio-Rad Laboratories).  Sequences of primers used are listed below: 
Gene Forward primer 5’ Reverse primer 3’ 
DGKα  5’ CAA TCA CAT CTG TGG GTG  CGA GGA 3’ 
5’ TTC CCG CCA CTC TTA 
GGA TTG AC 3’ 
DGKβ  5’ AAT GGA TCC TGA TCA TGA TGG AAC CGT GT 3’ 
5’ GAT GAA TTC CAC CAA 
ACA CAA TGC AGT CC 3’ 
DGKγ  5’ CTC ATG GGC GTC CGC AAG CA 3’ 
5’ CAT CCG GCA CCA CAG 
GCA GT 3’ 
DGKδ1 5’ GTG AAA GGG CAC CTT GAA AAC GC 3’ 
5’ CCC AGA CAG AGC CTC 
ACG GCA 3’ 
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DGKδ2 5’ GAA GCT CAT CCG CAA GGT GTC CAC G 3’ 
5’ ATT GCA GTA GGT CGG 
CCT CGC 3’ 
DGKη  5’ GTT GCT GCT TGG CTG GAT CTG CT 3’ 
5’ GCC ACA GAG GTG CTT 
CAG TGG TG 3’ 
DGKκ  5’ GAT GAA CAC CCA GGG CAA TAC AAT AG 3’ 
5’ ACC ATC AAT GGT TAT 
CAT CAC CTC ATG 3’ 
DGKε  5’ AGG GCC CTG CAC TGT CAC CA 3’ 
5’ AGG GGC ATG CTG CAG 
AGG AT 3’ 
DGKζ  5’ CGC CTG CCA TGG AGA CTT TCT TTA G 3’ 
5’ TTC ATG CCC ACA AGC 
CCG GTC 3’ 
DGKι  5’ AGG GGA TCC CAG GAG GGG AAA TGT AAG CA 3’ 
5’ CAA GAA TTC GCA AGG 
GTT TCA TGA GAG GA 3’ 
DGKθ  5’ ATG GGA TCC AGG ATC ACG ACA CCC ATC AC 3’ 
5’ ACG GAA TTC CGG AAC 
TGG CTT CTT CTC AC 3’ 
β-actin 5’ GGC ACC ACA CCT TCT ACA ATG 3’ 
5’ GTG GTG GTG AAG CTG 
TAG CC 3’ 
 
22.  Quantitative RT-PCR 
qPCR reactions were carried with the Power SYBR Green PCR Master Mix 
(Applied Biosystems) in a final volume of 8 µL.  GAPDH (human) or RPL3A (mouse) 
were used as controls. .  The primers used are detailed below: 
Gene Species Forward primer 5’ Reverse primer 3’ 
SREBP-1  Human 5’ TCA GCG AGG CGG CTT TGG AGC AG 3’ 
5’ GAG TCT GCC TTG ATG 
AAG TG 3’ 
SREBP-2 Human 5’ GGA TCA TCC AGC AGC CTT TGA 3’ 
5’ ACC GGG ACC TGC TGC 
ACC TGT 3’ 
FASN Human 5’ GAA ACT GCA GGA GCT GTC 3’ 
5’ CAC GGA GTT GAG CCG 
CAT 3’ 
ACC Human 5’ GCC TCT TCC TGA CAA ACG AG 3’ 
5’ GAC TGC CGA AAC ATC 
TCT G 3’ 
SCD1 Human 5’ CTA CAA ACC TGG CTT GCT GA 3’ 
5’ CCA GCC AGG TGG CAT 
TAA 3’ 
HMGCR Human 5’ CTT GTT GAA TGT CTT GTG ATT G 3’ 
5’ CTC TAA TAC CAA GGA 
CAC 3’ 
DGKα  Human 5’ CAA TCA CAT CTG TGG GTG  CGA GGA 3’ 
5’ TTC CCG CCA CTC TTA 
GGA TTG AC 3’ 
GAPDH Human 5’ ACA GCC TCA AGA TCA TCA GCA A 3’ 
5’ ATG GCA TGG ACT GTG 
GTC ATG 3’ 
DGKα  Mouse 5’ GTC TAC TGC TAC TTC ACC CTC C 3’ 
5’ CTT CCG TGC TAT CCA 
GGA TCC 3’ 
DGKα  
promoter 1 Mouse 
5’ CTC ACA CCA CCA TGC 
TGC TTC AAG AGT CCT G 3’ 
5’ GGC CCT TCT CTT TGG 
CCA TCC TTC TTC TC 3’ 
DGKα  
promoter 2 Mouse 
5’ GGC CGC GTC TTC CTA 
ACC CAG TCC CCT CC 3’ 
5’ GGC CCT TCT CTT TGG 
CCA TCC TTC TTC TC 3’ 
RPL3A Mouse 5’ TAA AGA CTG GAG ACA AGG TG 3’ 
5’ GTG TAC TCA GTC TCC 
ACA GA 3’ 
 
PCR conditions were as follows: 50ºC for 10 min, 95ºC for 2 min, 40 cycles at 95ºC 
15 s and 60ºC 1 min.  Reactions were run with the Applied Biosystems 7900HT system.  
Samples for each experimental condition were run in triplicate.  The relative expression 
of each gene was calculated from the fluorescence increase data vs. cycle number, from 
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which the Ct value is obtained; after correction for control amplification, the ΔCt is 
obtained.  Finally, the sample is compared with a reference sample, and the relative 
expression of the gene is calculated by applying the equation 2
€ 
−(ΔΔCt ) . 
 
23.  Induction of subcutaneous tumors with the MDA-MB-231 cell line 
and in vivo pharmacological treatment 
All mouse work was done in accordance with a protocol approved by the 
CNB/CSIC Ethical Committee for Animal Experimentation (CEEA-CNB).  MDA-MB-
231-shRNA-control, -shRNA-DGKα, and -shRNA-DGKζ cells (1.5 x 106) were 
injected subcutaneously in the flank of female BALB/c SCID mice aged 6-8 weeks.  
Tumor growth was monitored every two days and volume estimated according to the 
formula: volume = (a2 x b)/2, where a = tumor width and b = tumor length in 
millimeters.  At the end of experiment (when control tumors reached 1 cm3, ~30 days), 
tumors were weighed after sacrifice of the mouse and extraction of the tumor.  Tumors 
were then fixed overnight in paraformaldehyde, followed by dehydration in graded 
ethanol and embedded in paraffin for immunohistochemical studies. 
To assay the effect of R59949 and rapamycin on in vivo tumor growth, MDA-MB-
231 parental cells (1.0 x 106) were injected subcutaneously in the flank of female 
BALB/c SCID mice aged 6-8 weeks.  Pharmacological treatment was initiated when 
tumors reached at least 150 mm3 (~15 days).  Rapamycin and R59949 were 
administered intraperitoneally or subcutaneously, respectively, at a dose of 10 mg/kg 
every 48 h for 10 days.  Mice were sacrificed 48 h after the last dose, and tumors 
processed as above. 
 
24.  Analysis of DGKα  and DGKζ  expression in human breast 
samples 
DGK expression was analyzed in normal and tumor-derived human breast tissue 
from FFPE biopsies stored at the Hospital Clínico Universitario, Valencia, Spain.  We 
included five normal breast and nine tumor-derived samples.  Among the tumor-derived 
samples, five were classified as luminal, two as triple negative and two as HER2+.  
mRNA was extracted from samples with the High Pure FFPE RNA microkit (Roche) 
according to the manufacturer’s protocol.  Probes to DGKα, DGKζ and TBP (used as 
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control) were purchased from Applied Biosystems.  qPCR conditions were as described 
above. 
 
25.  Statistical analysis 
Data are represented as the mean ± SEM.  Statistical analysis was done with the 
GraphPad Prism 5 Software.  Student’s t-test was performed to compare data.  When 
the variance was significantly different, as analyzed with F-test, Welch’s correction was 
applied.  When the samples did not fit to normality, as tested with the Kolmogorov-
Sminorv test, the Mann-Whitney test was used.  When the p-value < 0.05, differences 
were considered statistically significant (* p<0.05; ** p<0.01; *** p<0.001). 
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1. ANALYSIS OF DGKα  AND DGKζ  ISOFORM EXPRESSION 
AND ACTIVITY IN BREAST CANCER AND NORMAL 
MAMMARY GLAND AND CORRELATION WITH THAT OF 
THEIR REGULATORS 
 
1.1. Determination of DGK expression and activity in breast cancer 
cell lines 
The DGK family comprises 10 isoforms, classified in five subgroups based on their 
domain structure (Merida et al., 2008).  Its expression is particularly enriched in the 
immune and the central nervous systems.  Most isoforms are expressed in epithelial 
lineages.  As there has been no analysis of DGK expression in the breast, our first aim 
was to identify which DGK isoforms are expressed in breast cancer and to compare 
DGK activity in normal and tumor cells.  We selected a panel of breast cancer-derived 
cell lines that include different oncogenic alterations and are representative of the 
distinct breast cancer subtypes (for details see Material and Methods).  As controls, we 
used two immortalized non-malignant cell lines of luminal (HB4a) and basal 
(MCF-10A) origin, which resemble the normal epithelium. 
 
Breast cancer cell lines expressed at least five DGK isoforms 
Our first approach to identify which DGK isoforms are expressed in breast-derived 
cell lines was to analyze their mRNA by RT-PCR.  mRNA levels do not always 
correlate with protein expression, but the lack of antibodies to all DGK isoforms 
rendered this the only suitable option for this analysis. 
RT-PCR analysis of five selected cell lines showed that at least five DGK isoforms 
were expressed in all cell lines.  We identified expression of type I DGKα, type II 
DGKδ and DGKη, type III DGKε and type IV DGKζ.  Type V DGKθ was observed 
only in basal-like cell lines (MCF-10A, MDA-MB-231 and MDA-MB-468).  In 
additional, type IV DGKι was detected only in the HER2+ cell line BT-474.  Type I 
DGKγ expression was nearly undetectable, and we considered it negative.  We did not 
detect type I DGKβ or type II DGKκ (Figure 8A). 
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DGK levels and activity are reduced in breast cancer-derived cell lines 
We next evaluated DGKα and DGKζ protein levels in the breast cell line panel, as 
DGKα and DGKζ are the best-characterized isoforms.  Several studies suggest that 
DGKα promotes cancer progression (Filigheddu et al., 2011), whereas array analyses 
indicate that DGKα acts as a tumor suppressor.  DGKζ has not been related to cancer 
onset; however, its redundancy with DGKα and the fact that it is a major DAG 
metabolizer necessitate analysis of its function in cancer progression. 
We first analyzed DGKα and DGKζ expression in untransformed cell lines of basal 
(MCF-10A) or luminal (HB4a) origin.  We found no great differences in the expression 
of these DGK isoforms between these cell lines (Figure 8B).  The MCF-10A cell line 
was used as an untransformed control.  DGKα expression was diminished in all tumor-
derived cell lines.  This reduction was more prominent in those cell lines bearing 
oncogenic alterations that lead to constitutive activation of the PI3K-Akt axis, including 
mutation in the p110α PI3K catalytic subunit (MCF-7), lack of the PTEN phosphatase 
(MDA-MB-468) or HER2 overexpression (BT-474).  DGKζ expression was higher in 
tumor lines than in untransformed cell lines, and was most strongly expressed in the 
MCF-10A cell line (Figure 8C). 
To analyze DGK activity, we performed two types of assays in crude cell extracts.  
In the first, C8-DAG micelles (as substrate) were formed directly in kinase assay buffer.  
This assay allowed measurement of total DGK activity.  If octyl glucoside (OGF) is 
added, DGKα activity is excluded; in these conditions, there are no differences in 
activity among cell lines, although HER2+ cells showed the lowest activity.  When 
DGK activity was measured without OGF addition, DGK activity paralleled DGKα 
levels; activity was higher in control untransformed cells and decreased in tumor cell 
lines.  Of the transformed cell lines, those bearing mutations in the p110α PI3K 
catalytic subunit (MCF-7, T-47D) or overexpressing the HER2 receptor (BT-474) had 
the highest activity (Figure 8D). 
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Figure 8.  DGK expression and activity in the breast-derived cell lines used in this study.  
(A) DGK isoform expression in the indicated cell lines was determined by analyzing mRNA 
expression in RT-PCR.  (B) Western blot comparison of DGKα and DGKζ in MCF-10A and 
HB4a cell lines.  (C) Western blot analysis of DGKα and DGKζ protein levels.  DGKα is 
expressed in the SK-BR-3 cell line, although at very low levels.  (D) DGK activity assay in 
whole cell extracts of the different cell lines was measured using C8-DAG as substrate, alone 
(top) or with octyl glucoside (bottom).  Each assay was performed at least three times.  A 
representative image is shown. 
 
DGK activity is coupled to the HER2 receptor in HER2+ cell lines 
The data above suggested that DGKα accounts for most of the changes in DGK 
activity observed in breast cancer cell lines.  DGKα is regulated by tyrosine 
phosphorylation, which stabilizes the enzyme in membranes.  We therefore measured 
DGK activity in phosphotyrosine immunoprecipitates.  In these conditions, we observed 
similar activity in the untransformed cell line and the highly malignant MDA-MB-231 
cell line.  The highest activity was observed in tumor-derived cell lines that overexpress 
RTK (EGFR in MDA-MB-468; HER2 in BT-474) or RTK scaffold (IRS-1 in MCF-7; 
Figure 9A).   
The BT-474 cell line, which overexpresses the HER2 RTK, showed the highest 
phosphotyrosine-coupled DGK activity.  Some DGK isoforms are regulated 
downstream of SFK (Cutrupi et al., 2000), and the increase in DGK activity could 
therefore be a result of increased SFK activity downstream of the receptor.  To 
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determine whether active DGK binds to the HER2 receptor, we immunoprecipitated 
HER2 from two overexpressing cell lines, BT-474 and SK-BR-3.  As a negative 
control, we used the HER2-negative MCF-7 cell line.  After incubation of HER2 
precipitates with DAG and ATP, we detected a product that comigrated with PA, 
confirming that active DGK is directly coupled to this receptor (Figure 9B). 
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Figure 9.  DGK activity is associated with phosphotyrosine and the HER2 receptor.  (A) 
DGK activity was measured in phospho-Y immunoprecipitates from cell lines, using C8-DAG 
as substrate.  (B) HER2 was immunoprecipitated and DGK activity assayed (top).  
Immunoprecipitation (center) and expression of HER2 (bottom) is shown in the cell lines used. 
 
DGKα  levels are regulated downstream of the PI3K pathway 
We thus observed that DGKα levels were diminished in breast cancer-derived cell 
lines, and that this reduction was more prominent in cell lines with oncogenic 
alterations in the PI3K axis.  A study from our laboratory suggests that through Akt-
mediated FoxO inhibition, DGKα is negatively regulated at the transcriptional level 
downstream of the PI3K-Akt axis (Martínez-Moreno et al., under revision).  There is 
increasing evidence of FoxO inactivation in tumors as a result of PI3K-Akt pathway 
hyperactivation.  To assess whether lack of FoxO function due to oncogenic activation 
of the PI3K-Akt pathway correlated with changes in DGKα expression, we used RT-
PCR to determine DGKα expression in breast cancer-derived cell lines showing 
aberrant PI3K pathway activation.  As a control, we included the MCF-10A cell line, 
which has no alterations in the PI3K axis.  DGKα gene expression was reduced in tumor 
cell lines compared to MCF-10A cells (Figure 10A).  Western blot experiments 
indicated inverse correlation between FoxO phosphorylation and DGKα protein levels 
in tumor and control breast cells (Figure 10B).  Even among tumor cells, variations in 
DGKα protein levels correlated to gene expression detected in RT-PCR and the degree 
of FoxO phosphorylation.  This is the case of the PTEN-deficient MDA-MB-468 cells, 
which showed the lowest DGKα and the highest FoxO1 phosphorylation levels. 
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Figure 10.  DGKα  expression correlates inversely with PI3K-Akt pathway activation in 
breast cancer cell lines.  (A) RT-qPCR quantification of DGKα mRNA levels in the cell lines 
compared to MCF-10A.  (B) Lysates of cell lines were resolved by SDS-PAGE; DGKα protein 
levels and FoxO1 and FoxO3 phosphorylation status were determined.  Blots were quantified 
with ImageJ.  Relative DGKα expression and FoxO phosphorylation are indicated (bottom).  
DGKα expression by MCF-10A cells = 100; pFoxO3a by BT474 cells = 100; pFoxO1 by 
MDA-MB-468 cells = 100. 
 
1.2. Analysis of DGKα  expression in the normal mouse mammary 
gland 
The mammary gland normally develops during puberty, which in mice takes place 
around 10-11 weeks after birth.  Mammary gland development involves cycles of ductal 
elongation, side branching and involution.  This is a highly proliferative process under 
hormone-dependent control (Brisken and O'Malley, 2010).  Microarray analyses place 
DGKα as a quiescence- and stemness-related gene (Merida et al., 2009).  We used 
qPCR to determine which mammary cells expressed DGKα, and compared the 
expression of this isoform before and after the onset of puberty. 
Enzymatic digestion of the mammary gland, followed by fluorescence-activated cell 
sorting (FACS) based on staining of the epithelial cell adhesion molecule (EpCAM) and 
α6-integrin (also referred as CD49f) allows the isolation of two populations (Stingl et 
al., 2006), basal or myoepithelial cells (EpCAMlow CD49fhigh) and luminal cells 
(EpCAMhigh CD49fmedium).  We observed that prior to (8 weeks) and after puberty (>11 
weeks), DGKα was expressed mainly in the luminal compartment.  At the onset of 
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puberty, expression was higher in basal-derived cells, which might correlate with 
increased luminal cell proliferation at this stage (Figure 11A). 
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Figure 11. qPCR analysis of DGKα  expression in the normal mouse mammary gland.  (A) 
Relative DGKα expression in luminal and basal mammary cells during post-birth development.  
Data are presented as the basal-luminal ratio.  (B) Analysis of relative DGKα expression in 
luminal subpopulations; variation in each subpopulation at the onset of puberty (top) and 
comparison of subpopulations before and during puberty (bottom).  (C) Relative expression of 
DGKα promoters in the distinct mammary cell populations.  Each assay was performed at least 
twice. 
 
The luminal cell population can be further divided into three subpopulations based 
on expression of Sca1 and α2-integrin (also termed CD49b) (Shehata et al., personal 
communication): alveolar progenitor (Sca1- CD49b+), double-positive or ER+ 
progenitor (Sca1+ CD49b+), and non-clonogenic or luminal differentiated cells (Sca1+ 
CD49b-).  We compared DGKα expression in these populations before and during 
puberty.  DGKα mRNA levels increased at the onset of puberty in both progenitor 
populations, whereas its levels remained constant in the non-clonogenic cells (Figure 
11B, top).  Whereas DGKα expression was higher before puberty (8 weeks) in the non-
clonogenic subpopulation, this pattern changed at 11 weeks, suggesting that DGKα is 
necessary for mammary cell differentiation programs (Figure 11B, bottom). 
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Expression of the DGKα gene is driven by the action of two promoters (Martínez-
Moreno et al., under revision).  We tested whether the expression of the two promoters 
was similar in mammary cells or if one was more prominent than the other.  qPCR 
analysis demonstrated that most DGKα gene expression in mammary cells is due to 
promoter 2 activity, whereas expression of promoter 1 was barely detectable (Figure 
11C).  These data indicate that DGKα expression depends on the mammary gland 
proliferative-differentiation stage. 
 
2. CONTRIBUTION OF DGKα  AND DGKζ  TO BREAST CANCER 
PROGRESSION 
 
2.1. DAG consumption by DGKζ  promotes SREBP-1 processing 
To sustain proliferation, tumor cells must adjust their metabolism by increasing the 
flow through biosynthetic pathways.  De novo lipid synthesis is normally increased in 
tumor cells, to generate the lipid membranes of daughter cells.  Several signaling 
pathways that ultimately regulate the SREBP family of transcription factors control 
lipid biosynthesis.  In addition, DAG and PA are central metabolites for lipid synthesis.  
We therefore tested whether DGK controlled the signaling and metabolic inputs that 
underlie lipid synthesis control. 
 
DAG levels increase after DGK inhibition and DAG accumulates in 
perinuclear regions in the MDA-MB-231 cell line 
To address DGK function in the regulation of tumor lipid metabolism, we used a 
broad spectrum DGK inhibitor, 3-[2-(4[bis-(4-fluorophenyl)methylene]-1-
piperidinyl)ethyl]-2, 3-dihydro-2-thioxo-4(1H) quinazolinone (DGK inhibitor II or 
R59949).  This drug is more potent than DGK inhibitor I, and blocks activity by binding 
to the DGK catalytic domain (Jiang et al., 2000).  Although R59949 is reportedly a 
selective inhibitor of Ca2+-dependent type I DGK isoforms in vitro (Jiang et al., 2000), 
it also inhibits other DGK classes in vivo (Avila-Flores et al., 2005; Chibalin et al., 
2008). 
Total DGK activity was assayed in lysates of breast cancer-derived MDA-MB-231 
cells treated with various concentrations of R59949.  The inhibitor reduced DGK 
activity by 50% at a 30 µM concentration (Figure 12A), which we established as the 
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IC50.  Since DGK regulates DAG levels, we measured lipid levels after prolonged (24 h) 
cell treatment with R59949.  Consistent with the reduction in DGK activity, total DAG 
mass was increased by 40% compared to vehicle-treated cells (Figure 12B). 
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Figure 12.  DGK inhibition leads to chronic DAG increase in intracellular membranes.  
(A) MDA-MB-231 cells in exponential growth were treated with DMSO or the indicated doses 
of the DGK inhibitor R59949 (24 h) and total DGK activity was evaluated.  (B) Total cellular 
DAG was determined using an in vitro radioenzymatic assay.  A representative autoradiogram 
is shown (mean ± SEM; n ≥3).  (C, top) DAG localization in DMSO- or R59949-treated MDA-
MB-231 cells was determined after transfection of the GFP-PKCθ C1b domain.  (C, bottom).  
Response of the PKCθ C1b domain to PMA was evaluated in the same conditions.  Student’s 
t-test; **p <0.01. 
 
DAG can be generated in distinct cell compartments from several sources, allowing 
the co-existence of different DAG pools, each of which has specific signaling and 
metabolic roles.  To study the sites at which DAG accumulates, we used the DAG 
sensor PKCθ C1b domain (Carrasco and Merida, 2004) and tracked its location in vivo 
after DGK inhibition.  Transfection of MDA-MB-231 cells with the GFP-fused PKCθ 
C1b domain showed that DAG accumulated mainly in a perinuclear region, whereas it 
was almost undetectable in the plasma membrane (Figure 12C, left column, top).  To 
confirm that the PKCθ C1b domain responded to DAG levels, we used the non-
permeable DAG analogue PMA (phorbol-12-myristate-13-acetate), which caused C1b 
translocation to the plasma membrane in vehicle-treated cells (Figure 12C, left 
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column, bottom).  Prolonged R59949 treatment led to the appearance of a signal in 
vesicles, that did not mimick PMA addition, while perinuclear staining was maintained 
(Figure 12C, right column, top).  In R59949-treated cells, PMA addition decreased the 
C1b signal in the perinuclear region, accumulated it at the plasma membrane, and was 
unaltered in the vesicles (Figure 12C, right column, bottom).  These results indicate 
that DAG accumulates in perinuclear regions and in vesicles, and not in the plasma 
membrane, when DGK activity is inhibited. 
 
DGK inhibition sustains PKD activation and affects Golgi apparatus structure 
DAG activates classical and novel PKC.  To test the effect of DAG increase, we 
treated MDA-MB-231 cells with R59949 for different times and measured phospho-
PKC substrates to analyze PKC activation; we found a slight increase in PKC activity as 
a result of DGK inhibition (Figure 13A).  In addition to activate PKC, DAG also 
activates PKD.  To be fully active, PKD must be phosphorylated at two sites, one 
formed by two residues within its activation loop domain (Ser744/8 for PKD1) whose 
PKC-dependent phosphorylation primes and relocates PKD, and the other comprised of 
a carboxy-terminal residue (Ser916 for PKD1), the result of autophosphorylation.  
PKC-dependent phosphorylation of PKD increased shortly after R59949 addition and 
was sustained for the duration of treatment (Figure 13B). 
Once activated, PKD localizes to the Golgi, where it promotes PtdIns-4-phosphate 
generation through activation of PI4KIIIβ (Yeaman et al., 2004).  PtdIns-4-phosphate is 
sensed by lipid transporters with a PH domain; we used the GFP-tagged PH domain of 
the ceramide transfer protein CERT to track PtdIns-4-phosphate accumulation.  In 
control cells, this lipid showed perinuclear accumulation, consistent with its Golgi 
location (Figure 13C), whereas in R59949-treated cells, perinuclear staining was lost 
and a vesicular pattern was observed throughout the cell (Figure 13C).  This is 
consistent with reports indicating that prolonged PKD activation leads to Golgi 
vesiculation.  To confirm this alteration in Golgi structure, we performed indirect 
immunofluorescence for the 130 kDa Golgi matrix protein (GM130).  DGK inhibition 
modified GM130 staining in a time-dependent manner, from a compact perinuclear to a 
multivesicular cytosolic signal (Figure 13D, E), reminiscent of the pattern for the 
PKCθ C1b domain.  This correlates with previous reports that show a critical 
contribution of DAG to maintain a correct lipid distribution in inner membranes, and 
thus the structure of organelles such as the Golgi (Baron and Malhotra, 2002). 
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Figure 13.  Inhibition of DGK sustains PKD activation and alters Golgi structure.  MDA-
MB-231 cells in exponential growth were treated with R59949 (30 µM) for the times indicated.  
Overall PKC (A) and PKD (B) activation status were measured by western blot.  (C) 
Fluorescence distribution of the Golgi lipid PtdIns-4-phosphate was evaluated in DMSO- or 
R59949-treated (6 h) MDA-MB-231 cells by localization of the GFP-tagged CERT PH domain.  
(D) Golgi integrity was evaluated by immunofluorescence of the GM130 protein in cells treated 
as in C).  (E) Time-dependent quantification (% cells with vesiculated Golgi; mean ± SEM) of 
cells processed as in D) is shown for at least three fields each in three independent experiments. 
 
Sustained inhibition of diacylglycerol kinase affects SREBP-1 processing 
These findings showed that DGK control the specific activation of DAG effectors in 
inner cell compartments, and are implicated in maintaining adequate lipid balance and 
Golgi integrity.  In addition to this signaling role, DAG is a biosynthetic precursor for 
several lipids.  Since the SREBP-1 transcription factor is a master regulator of lipogenic 
enzyme expression that senses lipid levels and is processed at the Golgi, we tested 
whether DGK contributes to SREBP-1 processing.  To evaluate the effect of DGK 
inhibition on total SREBP-1 levels, we treated MDA-MB-231 cells with R59949 for 
RESULTS 
 
 64 
various periods.  Levels of the full-length SREBP-1 form were the first to be reduced, 
whereas levels of the processed, active form decreased at longer treatment times 
(Figure 14A).  Since SREBP-1 controls the expression of its own promoter, we tested 
whether reduced SREBP-1 transcription activity was responsible for the early reduction 
in precursor levels.  qPCR analysis of SREBP-1 transcription activity indicated that 
SREBP-1 target expression as well of the gene itself were significantly reduced when 
DGK activity was inhibited, even at treatment times at which levels of the active short 
form had not yet been affected (Figure 14B).  Inhibition of DGK activity thus mainly 
affected SREBP-1 transcriptional activity. 
SREBP-1 activity depends on its subcellular location.  We used fractionation 
analysis of DGK-inhibited cells to assess whether the processed form enters the nucleus.  
DGK inhibition promoted a decrease in the full-length and intermediate forms of 
SREBP-1.  In addition, processed SREBP-1 levels were lower in the nuclear 
compartment, as this form accumulated in the cytosolic fraction; DGK inhibition thus 
prevented cytosol-nucleus translocation of mature SREBP-1 (Figure 14C). 
SREBP-1 translocation to the nucleus depends on its phosphorylation state, such 
that it remains cytosolic when phosphorylated	   (Li et al., 2011).  We tested whether 
SREBP-1 phosphorylation could be regulated in a DGK-dependent manner.  The 
processed SREBP-1 form has a consensus substrate sequence for PKC-PKD.  Western 
blot with a phospho-PKC substrate antibody showed that processed SREBP-1 was 
phosphorylated in the basal state; phosphorylation increased when DGK was inhibited 
(Figure 14D).  Treatment of cells with PKC and PKD inhibitors increased levels of 
both full-length and processed SREBP-1 (Figure 14E). 
As DGK inhibition led to an increase in total DAG levels, we determined whether 
this was the cause of altered SREBP-1 activity and processing.  In MDA-MB-231 cells 
treated with dioctanoyl-DAG, a non-metabolizable DAG form, we observed a slight 
increase in PKD activation, which correlated with reduced SREBP-1 levels 
(Figure 14F).  In a DGK assay of DAG-treated cells, we detected an increase in DGK 
activity that was sensitive to R59949 treatment (not shown).  Co-treatment with DAG 
and R59949 led to sustained PKD activation and early loss of SREBP-1 levels 
(Figure 14F).  These experiments indicate that SREBP-1 activation is DAG-sensitive, 
and that by controlling the levels of this lipid, DGK contribute positively to SREBP-1 
activity. 
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Figure 14.  DGK contributes to SREBP-1 processing and transcription activity.  (A) MDA-MB-231 
cells in exponential growth were moved to medium containing 1% FBS, treated with R59949 (30 µM) for 
the times indicated, and SREBP-1 levels were determined by Western blot.  (B) MDA-MB-231 cells were 
treated as in A) and mRNA levels measured by qRT-PCR.  Expression shown is relative to untreated 
controls.  (C) MDA-MB-231 cells were treated as in A), cytoplasmic and nuclear fractions were isolated, 
and levels of the indicated proteins analyzed by Western blot.  (D) MDA-MB-231 cells were treated with 
R59949 (30 µM, 16 h) and SREBP-1 immunoprecipitated.  PKC-mediated phosphorylation was analyzed 
by Western blot.  (E) MDA-MB-231 cells were treated with bisindolmaleimide (Bim) or Gö6976 (both at 
100 nM, 16 h) and SREBP-1 levels were analyzed by Western blot.  (F) MDA-MB-231 cells were treated 
(3 h) with R59949 (30 µM) or C8-DAG (100 µM) and full-length SREBP-1 levels analyzed by Western 
blot.  Data are representative of one experiment; n ≥ 3. 
 
Diacylglycerol kinase ζ  is responsible for most DGK activity in breast cancer 
cells 
The previous set of experiments suggested that the DGK pathway is a central 
regulator of DAG metabolism and signaling and therefore, that it controls SREBP-1 
processing.  Breast cancer-derived cell lines express various DGK isoforms.  To 
identify the major DAG regulators in breast cancer cells, we focused on DGKα and ζ.  
DGKα is implicated in cancer survival and is the main isoform inhibited by R59949 
(Jiang et al., 2000); DGKζ is regulated by PKC and its activity responds to DAG levels 
(Luo et al., 2003b) (Gharbi et al., 2011).  We used established RNAi sequences to 
downregulate DGKα and ζ expression (Avila-Flores et al., 2005), and found a ~90% 
reduction in protein expression by each of these isoforms (Figure 15A).  DGK activity 
assays of total cell extracts from RNAi-transfected cells indicated that whereas total 
DGK activity was unaffected by DGKα depletion, it decreased by ~50% when DGKζ 
levels were reduced (Figure 15B).  We used the same assay to assess the contribution 
of other isoforms, after pretreating cells with several concentrations of R59949 (24 h).  
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Control cells showed a 50% reduction in DGK activity at the highest inhibitor dose, as 
for untreated DGKζ-depleted cells.  When DGKζ-depleted cells were treated with 
R59949, however, we observed a further dose-dependent reduction in DGK activity, 
suggesting that a decrease in DGKζ permits R59949 access to other DGK isoforms that 
account for the remaining DGK activity in breast cancer cells (Figure 15C).  DGKζ 
would thus be the principal regulator of DAG levels in these cells. 
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Figure 15.  DGKζ  is the major contributor to DGK activity in MDA-MB-231 cells.  (A) 
DGKα and DGKζ levels in MDA-MB-231 cells transfected with siRNA for each isoform.  (B) 
Total DGK activity was evaluated in MDA-MB-231 cells transfected as in A).  (C) Total DGK 
activity in MDA-MB-231 cells transfected as in A) and treated with the indicated doses of 
R59949 (24 h).  Data shown for one representative assay (n ≥3). 
 
Diacylglycerol kinase ζ is the main PKC-PKD regulator and is necessary to 
maintain SREBP-1 processing 
Our results indicated that DGKζ is the main regulator of DAG levels in MDA-MB-
231 cells.  Abrogation of DGK activity led to a sustained increase in DAG levels that 
leads to alteration of DAG signaling effectors and lipid metabolism.  In addition to 
DGKζ, we studied DGKα, which is involved in tyrosine kinase receptor signaling and 
might contribute to SREBP-1 activation. 
To determine the isoform responsible for PKC and PKD regulation, we depleted 
each of these DGK isoforms in MDA-MB-231 cells and added R59949 to inhibit other 
DGK.  This inhibition led to an increase in total PKC activity in control cells and in 
PKC phosphorylation at the activation loop and the C-terminal hydrophobic motif, 
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needed to maintain an active PKC conformation (Figure 16A).  Depletion of DGKα or 
DGKζ increased PKC activity, which did not increase further after R59949 treatment.  
DGKα depletion increased PKC phosphorylation only at the activation loop, which is 
phosphorylated by PDK-1.  In DGKζ-depleted cells, PKC phosphorylation increased 
not only at the activation loop, but also at the hydrophobic motif, assumed to be the 
result of autophosphorylation (Figure 16A (Cenni et al., 2002)). 
PKD is activated by a combination of PKC triggering and DAG accumulation (Fu 
and Rubin, 2011).  Addition of a DGK inhibitor or reduction of DGKα levels promoted 
the appearance of slow-migrating bands corresponding to phosphorylated states of 
PKD; this effect was more prominent in DGKζ-depleted cells, in which PKD migrated 
as a fully phosphorylated form (Figure 16B). 
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Figure 16. DGKζ  depletion activates PKC-PKD signaling and abrogates SREBP-1 
processing.  DGKα and DGKζ expression was reduced in MDA-MB-231 cells by siRNA 
transfection.  (A) Transfected cells were treated with R59949 (30 µM) or DMSO (16 h).  PKC 
activity and phosphorylation status was evaluated by Western blot.  (B) Western blot evaluation 
of PKD activation in cells treated as in A).  (C) Western blot analysis of full-length and 
processed SREBP-1 levels in MDA-MB-231 with reduced DGKα or DGKζ levels.  n ≥3 for all 
experiments. 
 
In summary, these data indicated that DGKζ is the main isoform implicated in the 
homeostatic regulation of DAG levels and the activation of its signaling effectors in 
MDA-MB-231 cells.  By limiting DAG levels, DGKζ controls lipid metabolism 
through SREBP-1 regulation.  Depletion of DGKζ in MDA-MB-231 cells caused a 
reduction in SREBP-1 levels, which was more prominent in the precursor form.  This 
effect was DGKζ-specific, since reduction of DGKα did not alter SREBP-1 processing, 
nor was it further affected by R59949 addition to DGKζ-depleted cells (Figure 16C).  
DGKζ overexpression increased SREBP-1 levels as well as its processing, an effect not 
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observed when a kinase-dead form of the enzyme was expressed (not shown).  These 
data confirm that whereas both DGKα and DGKζ are able to regulate DAG effectors 
(the PKC-PKD axis), DGKζ has a critical metabolic role, as it is the main isoform 
involved in SREBP-1 control. 
 
2.2.  Contribution of the DGK pathway to the maintenance of the 
oncogenic axes that promote breast cancer progression 
The previous experiments show that DGK pharmacological inhibition results in 
DAG accumulation that strongly affects lipid traffic and metabolism.  DGK not only 
consume DAG, but also generate PA.  We next evaluated if lack of PA production as a 
result of DGK inhibition had also some impact on breast cancer progression. 
 
Diacylglycerol kinase inhibition abrogates Akt activation following rapamycin 
treatment 
The MDA-MB-231 cell line is highly invasive and, like other breast cancer-derived 
cell lines, is rapamycin-resistant (Sarbassov et al., 2006).  In these cells, high PA levels 
are suggested to reduce rapamycin sensitivity (Chen et al., 2003).  We showed that 
DGK activity was severely reduced by 30 µM R59949 (Figure 12A).  The effects of 
this dose were evaluated alone or in combination with rapamycin on mTOR substrates.  
Cell treatment with 100 nM rapamycin prevented mTORC1 activation, observed as a 
reduction in p70S6K phosphorylation and of its downstream substrate ribosomal protein 
S6 (rpS6; Figure 17A).  Rapamycin inhibition of mTORC1 correlated with increased 
Akt phosphorylation at Ser473.  R59949 alone had a minor effect on mTORC1 activity, 
but decreased Akt phosphorylation at Ser473.  Together with rapamycin, the DGK 
inhibitor abrogated rapamycin-induced Akt phosphorylation.  As a readout of Akt, we 
determined cyclin D3 levels.  R59949 (24 h) decreased cyclin D3 expression, further 
indicating a correlation between DGK activity and Akt (Figure 17A). 
In accordance with the effects of R59949 on S6K phosphorylation, short-term 
treatment with the inhibitor had little effect on mTORC1 assembly.  Rapamycin 
nonetheless strongly reduced the interaction between raptor and mTOR (Figure 17B).  
Short-term (1 h) DGK inhibition together with rapamycin treatment decreased rictor 
association to mTOR only slightly.  This effect was more pronounced after long-term 
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treatment (24 h); rapamycin dissociated 30% of the complex, whereas the use of both 
inhibitors reduced the amount of mTOR-associated rictor by nearly 80% (Figure 17B). 
These results concur with the differences reported in rapamycin sensitivity shown 
by both mTOR complexes.  The data also indicate that mTORC2 rapamycin sensitivity 
is clearly augmented by blocking a PA source, and that even when the mTOR/rictor 
complex is assembled, inhibition of DGK has a profound effect on Akt phosphorylation. 
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Figure 17.  DGK inhibition blocks Akt phosphorylation and cooperates with rapamycin to 
disrupt mTORC2 in MDA-MB-231 cells.  (A) To evaluate the DGK contribution to mTOR, 
cells were treated with R59949 (30 µM), rapamycin (100 nM), or both (1 or 24 h).  Total cell 
lysates were analyzed by Western blot using the indicated antibodies.  (B) Cells in exponential 
growth were treated as indicated (1 or 24 h) before lysis using CHAPS buffer.  Protein (1 mg) in 
lysates was used to immunoprecipitate mTOR.  Associated raptor and rictor were analyzed by 
Western blot.  mTOR complex integrity was determined as the ratio of immunoprecipitated 
raptor/mTOR and rictor/mTOR.  Mean ± SEM is shown for results from at least three 
independent experiments. 
 
Diacylglycerol kinase inhibition delays G1-S cell cycle progression in MDA-
MB-231 cells 
The PI3K-Akt-mTOR axis plays a positive role in the cell cycle, facilitating cell 
cycle entrance and allowing the transition between the G1 and S phases.  We examined 
the effect of R59949 and rapamycin treatment on mTOR activity throughout the cell 
cycle.  MDA-MB-231 cells were synchronized by serum deprivation, and rpS6 and Akt 
phosphorylation evaluated after serum readdition.  DGK inhibition decreased Akt 
phosphorylation, alone or in the presence of rapamycin (Figure 18A).  DGK inhibition 
markedly delayed cell cycle progression.  At 12 h post-serum addition, nearly 65% of 
RESULTS 
 
 70 
vehicle-treated cells were in S phase and rapamycin-treated cells had entered S phase 
after a delay, whereas the majority of R59949-treated cells were in G1.  DGK-inhibited 
cells resembled cells in a serum-starved state.  The effect of co-treatment with 
rapamycin and R59949 was similar to that of R59949 (Figure 18B, C). 
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Figure 18.  DGK inhibition delays Akt phosphorylation and G1-S progression in MDA-
MB-231 cells.  (A) Cells were serum-starved and cell cycle progression was followed after 
serum readdition.  DMSO, R59949 (30 µM) and rapamycin (100 nM) were added 1 h before 
serum.  Phosphorylation levels of S6 and Akt evaluated by Western blot.  (B) Flow cytometry 
analysis using propidium iodide staining to determine the percentage of cells in each cell cycle 
stage.  (C) The percentage of G0-G1 and S phase cells is indicated for the different treatments.  
* and # p <0.05 compared to vehicle or rapamycin, respectively.  
 
Diacylglycerol kinase inhibition promotes apoptosis of MDA-MB-231 cells 
Akt has a positive role in proliferation, but also in survival and apoptosis prevention 
(Manning and Cantley, 2007); the effects of DGK inhibition on survival and apoptosis 
prevention were therefore determined.  MDA-MB-231 cells were serum-starved and 
treated with different doses of the DGK inhibitor alone or together with rapamycin, and 
the apoptotic and death profile were determined using flow cytometry.  Rapamycin 
reduced the percentage of apoptotic cells, whereas the DGK inhibitor greatly increased 
this percentage (Figure 19A, B).  In agreement with the propidium iodide/annexin-V 
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data, DGK inhibition also increased PARP processing, another indicator of apoptosis 
(Figure 19C).  These data thus indicate that DGK activity is necessary to prevent 
apoptosis and maintain the survival of MDA-MB-231 cells. 
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Figure 19.  DGK activity prevents apoptosis of MDA-MB-231 cells.  (A) MDA-MB-231 
were serum-starved and treated (36 h) with R59949 or rapamycin at the indicated 
concentrations.  Apoptosis was measured by flow cytometry.  Data are from one representative 
experiment (n = 3).  (B) Mean of live, early apoptotic (annexin V+ propidium iodide-) and late 
apoptotic/necrotic cells (annexin V+ propidium iodide+) from n = 3 experiments.  (C) PARP 
cleavage was analyzed by Western blot of extracts from cells treated as in A). 
 
The diacylglycerol kinase effect on Akt Ser473 phosphorylation is independent 
of mTOR/rictor association 
Studies in mouse models have shown that mTORC2-Akt signaling is dependent on 
PI3K activity (Hietakangas and Cohen, 2007) (Chalhoub et al., 2009).  PI3K activity is 
also important in rapamycin-elicited mechanisms, since this drug is proposed to 
derepress various negative feedback loops that limit PI3K-Akt activation (Harrington et 
al., 2005).  We studied the effect of inhibiting DGK on mTOR complex formation and 
Akt phosphorylation in MCF-7 and MDA-MB-468 breast cancer cell lines.  In contrast 
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to MDA-MB-231, these two cell lines are not reported to have high PA levels, but show 
hyperactivation of the PI3K pathway.  MCF-7 cells have an oncogenic, activating 
mutation of the p110α PI3K catalytic subunit, whereas MDA-MB-468 cells do not 
express PTEN (Stemke-Hale et al., 2008). 
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Figure 20.  R59949 blocks Akt phosphorylation in breast cancer cells with hyperactive of 
PI3K signaling. (A-C) MCF-7, MDA-MB-468 and BT-474 cells in exponential growth were 
treated with DMSO, R59949 (30 µM), rapamycin (100 nM), or both (24 h).  Total cell lysates 
were analyzed by Western blot using the indicated antibodies.  One representative experiment is 
shown (n =3). 
 
In these cell lines, rapamycin reduced S6K/rpS6 phosphorylation, but did not 
modify Akt phosphorylation; DGK inhibition decreased mTORC1 activity, although not 
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to the same extent as rapamycin.  R59949 effects were small in MCF-7 cells, but 
pronounced in MDA-MB-468 cells.  R59949, alone or in combination with rapamycin, 
greatly reduced Akt phosphorylation (Figure 20A, B).  Results were similar in BT-474 
cells, which overexpress the RTK HER2 (Erbb2, Neu; (Neve et al., 2006), and thus also 
show increased PI3K signaling (Figure 20C). 
In contrast to MDA-MB-231 cells, mTOR complex assembly in MCF-7 and MDA-
MB-468 cells was more sensitive to DGK inhibition (Figure 21A, B).  In these cells, 
although rapamycin induced total disassembly of mTORC2, Akt phosphorylation was 
preserved. 
These data indicated that, in cells with a hyperactivated PI3K pathway, Akt Ser473 
phosphorylation can occur independently of mTOR/rictor assembly, supporting the 
existence of Akt Ser473 kinases in addition to mTORC2 (Troussard et al., 2006).  In 
this case, mTORC2-independent Akt phosphorylation requires DGK activity.  Although 
it contributes to mTOR complex assembly, DGK-derived PA thus has an additional, 
critical function as a positive modulator of the PI3K-Akt axis. 
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Figure 21.  DGK inhibition modifies mTOR complex assembly in breast cancer cells with 
hyperactivation of PI3K signaling.  (A, B) MCF-7 and MDA-MB-468 cells in exponential 
growth were treated with DMSO, R59949 (30 µM), rapamycin (100 nM), or both (24 h).  
Protein (1 mg) in CHAPS cell lysates was used to immunoprecipitate mTOR.  Associated raptor 
and rictor were analyzed by western blotting.  mTOR complex integrity was determined as the 
ratio of immunoprecitated raptor/mTOR and rictor/mTOR. Mean ± SEM is shown for results 
from at least three independent experiments. 
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DGK activity controls PI3K-Akt through generation of phosphoinositide 
intermediates and maintenance of phosphotyrosine signaling 
Our data indicated that DGK activity is needed for adequate PI3K signaling; DGK 
might therefore be necessary to allow PI3K activation by facilitating its coupling to 
phosphotyrosine platforms.  This is controlled by a balance between tyrosine and 
Ser/Thr phosphorylation of the receptors and scaffolds that dock PI3K through 
phosphotyrosine residues.  In muscle cells, lack of DGK activity is associated with PKC 
activation, which prevents insulin receptor substrate 1 (IRS-1) coupling to PI3K in 
response to insulin (Chibalin et al., 2008).  To determine whether the effect of DGK 
activity on Akt phosphorylation relies on the ability of DGK to modulate PKC 
signaling, we tested PKC inhibition on Akt Ser473 phosphorylation in MDA-MB-231 
cells.  PKC inhibition mimicked the effect of rapamycin on Akt phosphorylation; 
however, simultaneous inhibition of PKC and DGK activities abrogated Akt 
phosphorylation (Figure 22A).  This suggests that DGK effects on Akt phosphorylation 
are not PKC-mediated, and that DGK and PKC operate in parallel loops. 
We examined the profile of protein tyrosine phosphorylation in MDA-MB-231 cells 
treated with R59949, rapamycin or both.  DGK inhibition induced a sharp decrease in 
protein tyrosine phosphorylation (Figure 22B).  This finding suggested that DGK 
activity maintains a protein phosphotyrosine-mediated loop, which in turn might 
promote PI3K activity and Akt phosphorylation in response to rapamycin. 
DGK could also promote PI3K activity by providing a critical PtdIns pool.  The 
DGK are metabolic enzymes, and their essential function in PtdIns turnover is widely 
accepted (Jenkins et al., 1994) (Milne et al., 2008).  We thus measured PtdIns-4-
phosphate and PtdInsP2 levels in MDA-MB-231 cells treated for 24 h with R59949. 
DGK inhibition decreased the levels of both lipids (Figure 22C), but did not modify the 
amount of radiolabeled PA (not shown).  Treatment of the cells with LiCl, an inhibitor 
of inositol phosphatases and promoter of PA accumulation, reversed the effect of 
R59949 on Akt phosphorylation (Figure 22D).  LiCl did not affect GSK3 
phosphorylation (Figure 22D).  Our data thus indicate that R59949 modulates a specific 
PA pool responsible of PI3K and mTORC2 activity. 
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Figure 22.  R59949 reduces PtdIns intermediates and protein tyrosine phosphorylation.  
(A) MDA-MB-231 cells in exponential growth were treated with DMSO or with R59949 
(30 µM), the PKC inhibitor bisindolylmaleimide I (5 µM), or both (24 h).  Total cell lysates 
were analyzed by Western blot with indicated antibodies.  (B) The total protein phospho-Y 
profile was analyzed by Western blot in Triton-X100 lysates of MDA-MB-231 cells treated 
with R59949 (30 µM), rapamycin (100 nM), or both (24 h).  Ser 473 phosphorylation and total 
Akt were evaluated as controls.  (C) MDA-MB-231 cells were treated as indicated (24 h), 
followed by metabolic labeling (1 h) with 32P-orthophosphate.  Lipids were extracted and 
analyzed by TLC and HPLC.  PtdIns-4-phosphate and PtdInsP2 amounts are shown.  Results are 
shown for a single experiment performed in triplicate, of three performed with similar results.  
(D) Cells were seeded and treated as in A) but with LiCl (0.5 mM).  *p <0.05, ***p <0.001. 
 
DGKα  and DGKζ  control mTORC1 activity, but only DGKα  is required for 
Akt and Src activation 
The previous results indicated that DGK activity is essential for correct mTORC1 
and mTORC2 activation in breast cancer-derived cell lines.  To identify the isoform 
responsible for this effect, we used MDA-MB-231 cells depleted of DGKα or DGKζ.  
We first evaluated P70S6K activation following mitogenic stimulation.  A reduction in 
any DGK isoform abrogated P70S6K activation, measured as Thr389 phosphorylation 
at early times after serum addition (2 h; Figure 23A).  Nonetheless, the second peak of 
P70S6K activation (from 15 to 18 h post-stimulation) was only affected by DGKζ 
depletion (Figure 23A).  These data indicate that although both isoforms are necessary 
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for early mTORC1 activation, DGKζ is the main contributor to the activity of this 
complex, as it also affects the late activity peak. 
DGK also promoted Akt Ser473 phosphorylation.  In this case, the DGKζ reduction 
provoked a sharp decrease in Akt phosphorylation at this residue, but only depletion of 
DGKα completely abrogated it.  When we treated the cells with rapamycin, however, 
none of the DGK isoforms were able to revert rapamycin-induced Akt Ser473, at 
difference to findings for the DGK inhibitor R59949 (Figure 23B).  We observed an 
~90% reduction of protein levels with RNAi; rapamycin might therefore activate the 
remaining DGK or another isoform to promote Akt phosphorylation.  Akt activation 
requires PtdInsP3 generation by the PI3K, whose activity depends on tyrosine signaling.  
We analyzed activation of SFK, a family of non-RTK responsible for transducing and 
maintaining phosphotyrosine signaling.  Consistent with our previous observation, 
depletion of DGKα impaired Src activation (Figure 23C).  Our data therefore place 
DGKα as an essential regulator of Akt and SFK. 
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Figure 23.  Depletion of DGKα  and DGKζ  impairs P70S6K phosphorylation, but only 
DGKα  is necessary for Akt and Src activation.  (A) DGKα or DGKζ levels were reduced in 
MDA-MB-231 cells.  Cells were serum-starved (24 h) and allowed to enter the cell cycle after 
serum readdition.  P70S6K kinase phosphorylation was evaluated by Western blot.  (B) DGKα 
or DGKζ levels were reduced in MDA-MB-231 cells.  Cells were treated (24 h) with DMSO or 
rapamycin (100 nM).  Akt phosphorylation was evaluated by Western blot.  (C) Cells as in A).  
Src activation was analyzed by Western blot to detect tyrosine 416 phosphorylation.  Results are 
shown for one representative experiment (n =3). 
 
2.3. Contribution of DGK to the development of pharmacological 
resistance in breast cancer cells 
Our observations indicated that, by consuming DAG or generating PA, the DGK 
pathway makes a positive contribution to oncogenic axes responsible for breast cancer 
maintenance.  DGK activation could therefore be an intermediate in pharmacological 
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resistance pathways.  In addition, inhibition of DGK could promote the switching on of 
new pathways that could render the cell resistant.  We therefore evaluated whether 
DGK activity was activated as a result of pharmacological intervention, and if DGK 
inhibition promoted the activation of other oncogenic pathways. 
 
DGK is a component of the rapamycin-induced feedback loop that controls 
PI3K-Akt signaling 
Our findings in MDA-MB-231 cells indicated that DGK activity participates in the 
rapamycin-induced feedback loops, and that DGK activity is required for rapamycin-
induced Akt phosphorylation.  To better understand the molecular mechanism by which 
DGK modulates rapamycin responses, we evaluated DGK activity in membrane 
fractions of MDA-MB-231 cells after several pharmacological treatments.  As 
predicted, R59949 treatment inhibited DGK activity in this fraction.  Rapamycin 
treatment induced a sharp increase in DGK activity, which was prevented by R59949  
(Figure 24A, top).  We used an in vitro assay to assess the contribution of DGK 
activity to DAG levels by transforming endogenous DAG into PA.  In accordance with 
the data for endogenous DGK activity, DAG levels increased following DGK inhibition 
and decreased after rapamycin treatment (Figure 24B). 
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Figure 24.  DGK activity is induced by rapamycin treatment to promote PI3K signaling.  
(A) MDA-MB-231 cells in exponential growth were treated (24 h) as indicated.  DGK activity 
was determined in membranes (top) or in phosphotyrosine immunoprecipitates (bottom).  
Relative DGK activity is indicated beneath autoradiograms (DGK activity of vehicle-treated 
cells = 1.00).  (B) Total cell DAG was determined in an in vitro radioenzyme assay.  A 
representative autoradiogram and the mean ± SEM of at least three independent experiments are 
shown.  (C) PI3K activity was evaluated in phosphotyrosine immunoprecipitates.  Relative 
PI3K activity is indicated beneath the autoradiogram (PI3K activity of vehicle-treated cells = 
1.00). 
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One of the best-characterized feedback loops derepressed by rapamycin is the 
Ser/Thr phosphorylation of receptors and scaffolds responsible for tyrosine 
phosphorylation-mediated tethering of PI3K regulatory subunits to signaling complexes 
(Harrington et al., 2005).  Rapamycin treatment led to an increase in phosphotyrosine-
associated PI3K activity (almost four times control values).  The increase was reversed 
when DGK was inhibited (Figure 24C).  We also detected DGK activity in 
phosphotyrosine immunoprecipitates in both control and rapamycin-treated cells, but 
not following R59949 treatment (Figure 24A, bottom). 
These results led us to conclude that DGK activity parallels rapamycin-enhanced 
PI3K activation, suggesting that rapamycin triggers the generation of signaling lipids 
through activation of enzymes such as PI3K and DGK.  Our data also revealed that 
enhanced PI3K coupling to phosphotyrosine requires DGK activity. 
 
DGK inhibition does not reverse feedback mechanisms that rely on RTK-ERK 
activation 
Some tumors are refractory to current treatments, a resistance that is normally 
acquired from the unexpected activation of feedback loops elicited by the drugs 
themselves.  mTORC1 inhibition with rapamycin promotes not only PI3K-Akt 
activation, but also ERK activity as a result of derepression of mTOR-controlled 
feedback (Carracedo et al., 2008).  Inhibition of Akt is reported to increase RTK-
mediated signaling and ERK hyperactivation (Serra et al., 2011) (Chandarlapaty et al., 
2011).  At least in T cells, DGK inhibition promotes Ras-dependent ERK activation 
(Sanjuan et al., 2001).  As DGK inhibition inactivates the PI3K-Akt-mTOR axis, we 
tested whether it could switch on tyrosine and ERK signaling in breast cancer-derived 
cell lines, since this might promote resistance to a DGK-based pharmacological therapy.  
Treatment of breast cancer-derived cell lines with R59949 reduced total 
phoshphotyrosine signaling in all cell lines tested (Figure 25A). 
We next evaluated how DGK inhibition, alone or with rapamycin, affected ERK 
activation.  As expected, rapamycin maintained or increased ERK phosphorylation.  
Inhibition of DGK prevented ERK activation, since less ERK phosphorylation was 
observed, and reversed rapamycin effects (Figure 25B).  These data suggest that DGK 
activity is needed to sustain phosphotyrosine activity and that, in breast cancer cell 
lines, ERK activation might depend on DGK-produced PA. 
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Figure 25.  DGK inhibition prevents tyrosine and ERK signaling in breast cancer cells.  
(A) MDA-MB-231, MCF-7, MDA-MB-468 and BT-474 cells in exponential growth were 
treated with R59949 (30 µM; 24 h).  The phosphotyrosine profile was examined by Western 
blot.  (B) As in A), cells were treated with R59949 (30 µM) and rapamycin (100 nM).  ERK 
activation was evaluated by Western blot.  Data are from one representative experiment (n =3). 
 
DGKα  is necessary for HIF-1α  accumulation in MDA-MB-231 cells 
The hypoxia-inducible factor (HIF)-1α is a transcription factor whose accumulation 
is promoted by mTOR activation.  Accumulation of HIF-1α activates a transcription 
program that allows tumor cell adaptation to hypoxic environments and provides 
survival advantages, including resistance to chemo- and radiotherapy (Harris, 2002).  
As we observed that the DGK are central regulators of mTOR, we analyzed how the 
DGK affect HIF-1α.  We assessed the effect of inhibiting DGK on mitogen-induced 
HIF-1α accumulation.  Treatment of cells with R59949 abrogated HIF-1α accumulation 
in the MDA-MB-231 cell line after serum addition (Figure 26A).  We performed the 
same kind of experiments in cells transfected with RNAi to DGKα or DGKζ.  DGKζ 
depletion promoted a slight reduction in HIF-1α levels, which were clearly abrogated 
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by depletion of DGKα (Figure 26B).  These data suggest that DGKα is essential for 
HIF-1α accumulation in tumor cells, and confirm the relation between this isoform and 
mTOR activation. 
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Figure 26.  DGKα  is necessary for HIF-1α  accumulation after mitogenic stimulation.  (A) 
MDA-MB-231 cells were serum -tarved (24 h) and treated with DMSO or R59949 (30 µM; 
30 min).  Serum was added for the indicated times and HIF-1α levels analyzed by Western blot.  
(B) MDA-MB-231 cells were depleted of DGKα or DGKζ.  Cells were serum-starved (24 h), 
and stimulated for the indicated times.  HIF-1α accumulation was evaluated by Western blot.  
Results are from one representative experiment (n =3). 
 
3. RELEVANCE OF DGK EXPRESSION AND/OR ACTIVITY FOR 
BREAST CANCER INITIATION AND PROGRESSION IN VIVO 
Our results indicated that DGK activity is central to the control of DAG levels to 
maintain adequate lipid metabolism of tumor cells.  In addition, DGK operates through 
several interconnected mechanisms, to maintain the supply of PtdIns that drives the 
PI3K-Akt-mTOR axis in breast cancer cells.  Targeting DGK could thus impair/reduce 
tumor growth, alone or in combination with other treatments. 
 
DGK inhibition impairs breast cancer cell proliferation in vitro 
To study the potential for pharmacological intervention in this pathway, we assessed 
the effect of DGK inhibition on long-term growth of MDA-MB-231 cells in colony 
formation assays of cells cultured for several days with various doses of R59949.  
Inhibitor treatment led to a reduction in colony number, and 20 µM R59949 resulted in 
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~50% reduction in cell growth (Figure 27A).  Short-term rapamycin treatment did not 
alter the growth of these cells, but long-term treatment reduced colony numbers.  This 
observation concurs with a report showing the effects of rapamycin on long-term 
growth of MDA-MB-231 cells (Breuleux et al., 2009).  Combined treatment with both 
drugs slightly reduced cell growth when <20 µM DGK inhibitor was used, indicating an 
additive effect (Figure 27A, C). 
The effects of R59949 on colony formation were also evaluated in the cell lines with 
a hyperactivated PI3K pathway.  In these cells, DGK inhibition markedly reduced 
colony number (Figure 27B, C).  R59949 sensitivity was inferred by comparing the 
IC50 for each cell line.  MDA-MB-231 cells showed the highest IC50 (22 µM), whereas 
cells with increased PI3K activity had a lower IC50 (12 to 18 µM; Figure 27D).  These 
variations in sensitivity to DGK inhibition support a relationship between DGK activity 
and aberrant PI3K activation, as well as the differences in sensitivity of both complexes 
to rapamycin and DGK inhibitor. 
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Figure 27.  DGK inhibition impairs cell proliferation in breast cancer-derived cell lines.  
(A) Colony growth formation assays were performed using MDA-MB-231 cells treated 
(10 days) with DMSO, R59949 and/or rapamycin (10 nM).  (B) Colony growth formation 
assays were evaluated in MCF-7, MDA-MB-468 and BT-474 cells treated (10 days) with 
DMSO or R59949.  (C) Crystal violet staining was quantified to evaluate colony number and 
size.  (D) IC50 of R59949 was determined for each cell line.  Data show mean ± SEM for 
triplicate samples from one representative experiment (n ≥3; triplicates for each condition).  
Student’s t-test, *p <0.05; ** <0.01; *** <0.001. 
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Diacylglycerol kinase ζ  is necessary to maintain proliferation of breast cancer 
cells in vitro 
Using the same assay, we tested the effect of DGKα or DGKζ reduction.  DGKα 
depletion did not affect MDA-MB-231 cell growth, whereas DGKζ depletion 
significantly compromised cell growth in vitro, which was reduced by ~50% (Figure 
28).  This finding confirms the central role of DGKζ in the control of metabolism and 
promotion of tumor growth. 
Scramble DGKα DGKζ
RNAi
 
Figure 28.  DGKζ  is necessary for breast cancer cell colony growth.  Colony growth 
formation assays were performed using MDA-MB-231 cells with stably reduced DGKα or 
DGKζ levels; crystal violet staining (left) and quantification of absorbance at 620 nm (right).  
The data show a representative experiment (n ≥3; triplicates for each condition).  Student’s 
t-test, ***p <0.001. 
 
Diacylglycerol kinase inhibition impairs breast tumor growth in vivo 
The previous experiments suggested that DGK inhibition could impair or reduce in 
vivo tumor growth.  We tested this by assessing the effect of R59949 in a preclinical 
study of heterotopic tumor generation in immunocompromised (SCID) mice; we used 
the MDA-MB-231 cell line to produce tumors, since this line is highly aggressive and 
had the highest IC50 to the drug, although it remained R59949-sensitive.  When tumors 
reached 150 mm3, mice were randomly separated into two groups, and we established 
an R59949 administration schedule using the maximum inhibitor dose that showed no 
toxic effects by subcutaneous delivery.  Administration of R59949 
(10 mg/kg/treatment) severely inhibited tumor growth (Figure 29A).  Akt Ser473 
phosphorylation and cleaved caspase 3 were evaluated by immunohistochemistry (IHC) 
in tumors.  R59949 treatment decreased Akt Ser473 phosphorylation signal, and 
markedly increased the cleaved caspase staining (Figure 29B). 
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Figure 29.  DGK inhibition impairs growth of MDA-MB-231-induced tumors.  (A) 1.0 x 
106 cells were injected into immunocompromised mice.  When tumors reached ~150 mm3, 
vehicle or R59949 (10 mg/Kg/48 h) were administered s.c. for several days.  Tumor volume 
was recorded every third day to obtain a growth curve (left).  At the end of the treatment, mice 
were sacrificed, tumors extracted and weighed (right).  (B) Tumor sections were immunostained 
for phosphorylated Akt (Ser473) or cleaved caspase 3, together with hematoxylin. A 
magnification is shown in the inset.  (C) As in A), except that 1.5 x 106 cells were injected into 
mice and rapamycin (10 mg/Kg/48 h) was administered alone or with R59949. *p <0.05; 
**<0.01; *** <0.001 compared to vehicle. ##p <0.01; ### <0.001 compared to rapamycin.  The 
data show mean ± SEM for a representative experiment of at least three performed (n = at least 
6 mice/group). 
 
In another set of experiments, we administered rapamycin alone or with R59949.  
Rapamycin delayed the tumor growth rate only at the outset of treatment.  The DGK 
inhibitor again reduced tumor growth, and showed a greater effect when combined with 
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rapamycin (Figure 29C).  These data indicate that, in addition to reducing tumor 
progression on its own, R59949 could be applied in combination with rapamycin to 
treat tumors with characteristics similar to those of MDA-MB-231 cells. 
 
Diacylglycerol kinase α  is essential to sustain breast tumor growth in vivo 
The previous experiments suggested that DGKζ has a major metabolic and signaling 
role, and that its inhibition reduced in vitro tumor growth.  DGKα had minor effects, 
but was a critical regulator of tyrosine phosphorylation.  We assessed the effect of 
depleting DGKα and DGKζ in MDA-MB-231 cells in a mouse xenograft model.  
DGKζ-depleted cells grew more slowly in vivo than control MDA-MB-231 cells, 
measured as the x-fold change in tumor volume.  Cells lacking DGKα initially grew at 
the same rate as control cells, but tumors finally stopped growing and began to decrease 
in size (Figure 30A).  When tumors were extracted and weighed, however, only those 
originating from DGKα-depleted cells were significantly smaller (approximately 50%; 
Figure 30B). 
 
Figure 30.  DGKα  is necessary for breast tumor growth in vivo.  1.0 x 106 MDA-MB-231- 
shRNA-control, -shRNA-DGKα or -shRNA-DGKζ cells were injected into 
immunocompromised mice.  Tumor volume (when ~150 mm3) was recorded every two days for 
two weeks to obtain a growth curve (left).  At the end of the treatment, mice were sacrificed, 
tumors extracted and weighed (right). ***p <0.001.  The data show mean or mean ± SEM for a 
representative experiment of at least three performed (n = at least 6 mice/group). 
 
Diacylglycerol kinase α  is needed for MDA-MB-231 cells growth in 3D culture 
These data suggest that DGKα is necessary for the in vivo growth of MDA-MB-
231-derived tumors, although it has a modest effect on cell growth in vitro.  New 
evidence suggests that the expression and function of many genes differs in epithelial 
cells, depending on whether they are cultured in 2D or in 3D matrices that mimic the 
ECM structure (Kenny et al., 2007).  We thus tested whether this was the case for 
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DGKα.  As a first approach, we assessed whether DGKα activity or levels depended on 
cell contact.  Seeding of MDA-MB-231 cells at various confluences indicated that DGK 
activity and DGKα protein levels increased as the culture became more confluent 
(Figure 31A). 
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Figure 31.  DGKα  is necessary for MDA-MB-231 cell growth in 3D culture.  (A) MDA-
MB-231 cells were seeded at different densities.  DGK activity was measured in whole cell 
extracts and DGKα analyzed by Western blot.  (B) MDA-MB-231 cells were seeded on top of 
matrigel (4 days).  RNA was extracted and DGKα mRNA expression analyzed by qPCR.  (C) 
MDA-MB-231-pLKO-TetON-shDGKα cells were embedded in matrigel and allowed to grow 
for 12 days, alone or with doxycycline (100 ng/mL).  Cells were stained with DAPI (blue) and 
rhodamine-phalloidin (red).  (D) ILK was immunoprecipitated and DGKα detected by Western 
blot.  Data are representative of one experiment (n = 3). 
 
We next analyzed whether DGKα expression changed in 2D compared to 3D 
culture.  We established an “on-top” matrigel culture and compared DGKα expression 
by qPCR.  DGKα mRNA levels increased by nearly 3-fold when grown on ECM 
(Figure 31B).  This increase suggested that DGKα could be needed to establish and 
maintain correct tissue architecture.  We thus monitored the effect of DGKα deficiency 
on the growth of matrigel-embedded cells.  We established stable MDA-MB-231 cells 
that could be DGKα-depleted in a doxycycline-dependent manner.  When DGKα was 
reduced, MDA-MB-231 formed fewer and smaller groups than control cells (no 
doxycycline addition).  DAPI staining of DGKα-depleted MDA-MB-231 cells showed 
that this could be a result of increased cell death, as more bubbling-staining was 
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observed (Figure 31C).  Moreover, we found that DGKα associated to the integrin-
linked kinase (ILK), a protein involved in the transduction of signals from the ECM 
(Figure 31D).  These data could help to explain why DGKα depletion impaired in vivo 
tumor growth.  Further studies are nevertheless required to establish a causal relation 
between DGKα and the 3D growth of tumors. 
 
4. A REFERENCE FRAMEWORK TO EVALUATE THE 
POTENTIAL OF THE DGK PATHWAY AS A TARGET FOR 
THERAPEUTIC INTERVENTION 
Our data indicated that DGKα and DGKζ play a positive role in breast cancer 
progression.  DGKζ controls DAG levels to maintain tumor lipid metabolism and 
promotes tumor proliferation in vitro.  DGKα nonetheless appears to be critical for 
tumor growth and maintenance in vivo.  Inhibition of DGK proved effective in 
impairing tumor development.  We also found that the DGK pathway can be a 
component of loops that promote resistance to tumor therapies.  DGK targeting could 
thus be a promising approach for the treatment of breast cancer.  As it is necessary to 
determine how DGKα and DGKζ levels are affected in patient samples, we first 
determined the relative expression of both isoforms in normal human breast, using 
formalin-fixed paraffin-embedded (FFPE) sections.  qPCR analysis showed that DGKα 
was the most expressed isoform, with expression 34 times higher than that of DGKζ 
(Figure 32A). 
We next compared the expression of the two isoforms in normal and malignant 
tissue.  DGKα levels were increased in tumor samples, which did not include any 
samples of the HER2+ subtype (Figure 32B).  We analyzed DGKα levels in two HER2+ 
breast tumors and found that DGKα expression was reduced by almost 80% compared 
to normal tissue (not shown).  There were no differences in DGKζ levels between 
normal and malignant tissue (Figure 32C).  Although these data are preliminary, 
combined with our previous observations, these findings allow us to hypothesize that 
certain DGKα levels might drive breast cancer progression, and could be effectively 
targeted for the treatment of breast tumors. 
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Figure 32.  DGKα  and DGKζ  expression in human normal and tumor-derived breast 
tissue.  DGKα and DGKζ expression was evaluated by qPCR in FFPE tissue sections.  (A) 
Relative expression of DGKα and DGKζ in the normal breast (n = 5 samples).  Relative 
expression of DGKζ was used as control.  (B) Relative expression of DGKα in normal (n = 5) 
and tumor-derived tissue (n = 9).  (C) Relative expression of DGKζ in normal (n = 5) and 
tumor-derived tissue (n = 9). 
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1.  Strong DGKα  expression in untransformed mammary cells 
suggests a tumor suppressor role 
The DGK are a large family of lipid kinases whose functions have been broadly 
characterized in the immune and central nervous systems.  At present, the only data that 
suggest a role for DGK in cancer are derived from microarray analyses; they mainly 
implicate the DGKα isoform, and there are no extensive studies on the contribution of 
specific DGK isoforms to the malignant phenotype. 
In our study, we determined the expression pattern of the DGK isoforms in normal 
and breast cancer-derived cell lines.  RT-PCR analysis of DGK expression in five 
selected cell lines showed that each cell line expressed at least five DGK isoforms.  We 
then focused on the study of DGKα and DGKζ.  Several studies implicate DGKα in 
tumor progression, but its function is debated, as it might have roles both as a tumor 
promoter and a tumor suppressor (Merida et al., 2009).  At least in the immune system, 
DGKζ is highly redundant with DGKα, and mice deficient in either isoform share a 
phenotype with T cell hyperresponsiveness and resistance to anergy (Olenchock et al., 
2006; Zhong et al., 2003).  In our study, DGKα protein levels were severely reduced in 
all tumor-derived cell lines, whereas those of DGKζ tended to be higher in breast cancer 
cell lines.  The reduction in DGKα was more prominent in those cell lines bearing 
mutations that lead to aberrant activation of the PI3K-Akt axis.  We show that DGKα 
mRNA levels as analyzed by qPCR are significantly reduced in these cell lines 
compared to the untransformed MCF-10A cell line, and that they correlate inversely 
with the degree of phosphorylation of FoxO transcription factors.  Hyperactivation of 
the PI3K-Akt axis leads to constitutive phosphorylation of FoxO, causing its 
inactivation.  Our laboratory described three putative FoxO-binding sites in the DGKα 
gene promoter, which explains why DGKα is reduced in this subgroup of breast cancer-
derived cell lines.  This regulation appears to be DGKα-specific, as other isoforms such 
as DGKζ, are not regulated by FoxO- or PI3K-Akt-dependent mechanisms (Martínez-
Moreno et al., under revision). 
We tested whether DGKα expression correlated with DGK activity in our cell 
panel, and found that total DGK activity was higher in the untransformed cell line 
MCF-10A; the differences observed among the cell lines can be explained in terms of 
differential DGKα expression. 
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The characterization of FoxO-mediated regulation of DGKα throws new light on the 
conflicting data regarding the contribution of DGKα to malignant transformation.  
Studies of lymphoma and epithelial cells indicate that DGKα activity is coupled to 
tyrosine signaling (Bacchiocchi et al., 2005; Baldanzi et al., 2004; Cutrupi et al., 2000), 
and that DGKα-mediated PA generation promotes Rac and PKCζ activation (Chianale 
et al., 2010); the authors thus propose a positive DGKα contribution to tumor survival, 
angiogenesis and/or migration.  Conversely, DGKα is reported to have negative 
functions in malignant transformation.  DGKα gene expression is positively linked to 
lung cancer patient survival (Berrar et al., 2005), and reduction of its expression is 
synergistic with p53 and Ras mutations in colon cancer (McMurray et al., 2008).  The 
identification of FoxO-dependent DGKα regulation further supports a relationship 
between cell transformation and reduced DGKα expression.  A decrease in DGKα 
levels could lead to a concomitant loss of its DAG-brake functions that, in tumor cells, 
is linked to the onset of malignant transformation.  Lower DGKα levels in transformed 
cells would switch DGKα requirements to those of PA-mediated regulation of tyrosine 
kinases and/or atypical PKC. 
We found that in breast-derived cells, independent of their untransformed or 
malignant character, DGK activity and specifically, DGKα levels increased as the cells 
reached high confluence.  This behavior appears to differ from that described by Morita 
and coworkers (Morita et al., 2009).  Using HEK-293 cells, these authors observed that 
PA levels decrease as a culture becomes more confluent, an effect they attribute to 
DGKζ.  At difference from HEK-293, the cell-cell contacts of breast-derived cell lines 
can be more robust or differentiated.  One type of cell-cell contact is that mediated by 
cadherins, responsible for adherens junction formation.  Cadherins form complexes with 
the α- and β-catenins, which link cell adhesion molecules to the cytoskeleton.  Catenins 
can also interact with the transcription factor lymphoid enhancer-binding factor 1 
(LEF-1) to modulate gene expression (Behrens et al., 1996).  Tthe DGKα promoter has 
one LEF-1 site (Martínez-Moreno et al., under revision) and it is likely that, as cells 
reach confluence, LEF-1 signaling modifies DGKα expression. 
DGKα might be also needed for the formation and/or maintenance of tight 
junctions, a specialized type of junction established in endothelia and epithelia.  This 
junction is composed of distinctive integral proteins (claudins and occludins) that bind 
through cytoplasmic plaque adaptor proteins to the actin cytoskeleton	   (Gonzalez-
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Mariscal et al., 2008).  Tight junctions also contribute to the maintenance of the apical 
and basolateral domains of polarized epithelial cells.  Epithelial polarity is controlled by 
various proteins, among them the PAR complex, which includes Par3, Par6 and aPKCζ.  
aPKCζ is recruited to subapical Par3-Par6 complexes, and phosphorylates and excludes 
Par3 from tight junction sites, allowing junction formation and the separation of the 
apical and subapical domains (Martin-Belmonte and Perez-Moreno, 2012).  DGKα-
generated PA regulates aPKCζ, to promote cell migration	  (Chianale et al., 2010).  This 
isoform probably also contributes to other aPKCζ-mediated processes in epithelial cells, 
such as the establishment of a polarized epithelium. 
We also show that DGKα interacts with the ILK.  The ILK is a protein that interacts 
specifically with the β1- and β3-chains of integrins, the major cellular ECM receptors.  
There is controversy as to whether ILK is a true protein kinase or only a docking 
pseudokinase protein (Wickstrom et al., 2010).  In any case, ILK plays a central role in 
the transmission of signaling events initiated by cell-matrix interactions (McDonald et 
al., 2008a).  DGKα was recently shown to regulate integrin recycling through PA-
dependent RCP regulation (Rainero et al., 2012).  These data suggest that DGKα is 
tightly coupled to the transduction of signals from cell-cell and cell-ECM interactions.  
We propose a tumor suppressor role for DGKα that helps to preserve the quiescence 
state and it contributes to the formation and maintenance of cell-cell contacts and 
epithelial polarization. 
This function correlates with the changes in DGKα expression observed in the 
normal mouse mammary gland.  The mammary gland is a complex organ constituted of 
cells of diverse origins.  To prevent contamination by other lineages, especially by 
lymphoid cells (which express high DGKα levels), we used a flow cytometry cell 
sorting technique to isolate mammary epithelial cells.  In addition, this approach allow 
us to distinguish between basal and luminal epithelial cells, as well as the different 
luminal subsets.  Age-dependent analysis showed that DGKα mRNA levels are higher 
in luminal than in basal cells; this pattern changed during puberty (10-11 weeks after 
birth).  We also analyzed DGKα expression in different luminal compartments, and 
observed that its expression increased at the onset of puberty.  This DGKα increase was 
observed mainly in the double positive (or ER+) and the alveolar progenitors, whereas 
levels remained invariable in the non-clonogenic or differentiated luminal population.  
These data are consistent with those found in array analyses.  A GEO database search 
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(Edgar et al., 2002) (accession GDS2360 and GDS2721) showed that DGKα is 
expressed strongly during puberty and diminishes during pregnancy, lactation and 
involution (not analyzed here). 
We have recently characterized the presence of two independent promoter regions 
that drive DGKα expression (Martínez-Moreno et al., under revision).  We found that 
the most active promoter in mouse mammary epithelial cells is promoter 2.  This 
contrasts with other cell types, such as T cells, in which DGKα is driven mainly by 
promoter 1 (García-Liévana, unpublished observations).  In silico analysis of DGKα 
promoter 1 showed that it has a STAT-binding site, which is thought to repress the 
transcription activity of this promoter (Verdeil et al., 2006).  The activity of these 
transcription factors is high in the developing mammary gland (Visvader, 2009).  
Although further studies are required, these data link DGKα expression with the 
proliferative-differentiation state of the mammary gland. 
 
2.  DGKα  and DGKζ  contribute to the maintenance of lipid 
metabolism and oncogenic axes in breast cancer 
The DGK balance the levels of two lipids that lie at the core of lipid biosynthesis 
pathways and of the oncogenic axes that help to maintain the malignant phenotype.  
Further analysis of the DGK contribution to these processes could help to determine 
whether they function as tumor promoters or suppressors, as well as the mechanisms 
responsible for this dual behavior. 
2.1.  DAG consumption helps to maintain the lipogenic metabolism of breast 
tumors 
We first focused on the roles of DGKα and DGKζ in the control of breast cancer 
lipid metabolism (Figure 33).  The targeting of tumor metabolism promises new 
opportunities for cancer treatment.  Inhibition of DGK in breast cancer cells caused a 
chronic increase in DAG levels.  As a lipid second messenger, DAG integrates signaling 
and metabolic functions, which might be a way in which cells join several mechanisms 
to regulate lipid metabolism.  We used a DAG-specific fluorescent probe to show that, 
in exponentially growing cells, DAG accumulates mainly in the Golgi apparatus.  DAG 
is generated in the Golgi mainly by sphingomyelin synthase action, which transforms 
ceramide and PtdCho into sphingomyelin and DAG.  DGK inhibition causes increased 
DAG levels in Golgi and in vesicles, and as a result, might alter the morphology of and 
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distribution of lipids in the Golgi.  DAG increase thus promotes PKD activation, which 
in turn triggers PtdIns-4-phosphate production via PI4K activation	   (Yeaman et al., 
2004).  PtdIns-4-phosphate serves as a docking site for several lipid transporters, such 
as CERT and OSBP (oxysterol-binding protein), responsible respectively for ceramide 
and oxysterol trafficking from the endoplasmic reticulum to the Golgi.  This helps to 
maintain a continuous lipid flow within the cell compartments.  An excessive 
production of DAG limits lipid transport through PKD hyperactivation, which in turn 
phosphorylates the CERT and the OSBP PH domains and impairs their binding to 
membranes	  (Malhotra and Campelo, 2011).  This mechanism by which DAG-dependent 
regulation of PKD promotes or limits lipid transport from the endoplasmic reticulum to 
the Golgi helps the cells maintain a correct supply of lipids with important structural 
functions, such as PtdCho. 
An excess of DAG together with lack of PA production helps to explain the 
profound alteration in Golgi structure that results from DGK inhibition.  This phenotype 
resembles that found after cell treatment with ilimaquinone, a natural metabolite of 
sponges that vesiculates the Golgi apparatus by overactivating the membrane fission 
reaction.  This reaction implicates DAG accumulation at the neck of the new vesicle.  
DAG generation triggers PKD localization and dimerization in the trans-Golgi network 
(TGN,	  (Baron and Malhotra, 2002)).  Vesicle fission is terminated by the accumulation 
of less-stable lipids such as PA.  PA is generated in two ways; one involves PKD-
mediated activation of the PLD via the Arf family of GTPases, which produces PA 
from PtdCho hydrolysis.  PA can also be produced from DAG by the action of a DGK, 
a reaction that additionally reduces DAG levels and delocalizes PKD from the TGN 
(Malhotra and Campelo, 2011).  In our experiments using MDA-MB-231 cells, the 
DAG-dependent functions are likely to be mediated by the PKD2 or PKD3 isoforms, as 
this cell line lacks PKD1 (Eiseler et al., 2009). 
In addition to its function in the control of lipid distribution within the cell, the 
Golgi is also the site at which several proteins are modified.  An example is the 
transcription factor SREBP-1, whose active form is generated at the Golgi after 
cleavage by two proteases	   (Osborne and Espenshade, 2009).  We demonstrate the 
contribution of DGK activity to SREBP-1 activation (Figure 33).  DGK inhibition can 
affect SREBP-1 processing through several non-exclusive mechanisms. 
a.  DGK can affect SREBP-1 processing by controlling DAG signaling effectors 
(Figure 33).  We demonstrate that PKC or PKD inhibition leads to an increase in full-
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length SREBP-1 levels.  Since SREBP-1 controls its own gene expression, it is probable 
that DAG effectors control its transcriptional activity.  SREBP-1 transcription activity 
depends on its nuclear location, which for most transcription factors is regulated by 
phosphorylation.  This is the case of SREBP-1, whose phosphorylation by AMPK 
(AMP-activated protein kinase) impairs processing of the full-length form as well as 
nuclear translocation of the active factor	  (Li et al., 2011).  A similar mechanism might 
operate when DAG levels increase.  Here we show that treatment with DGK inhibitor 
causes a migration shift of full-length SREBP-1.  In addition, cell treatment with 
inhibitors of PKC or PKD catalytic activity promotes expression of the SREBP-1, thus 
suggesting that by inhibiting DAG effectors, DGK also promotes SREBP-1 processing 
and translocation to the nucleus, where it triggers its own transcription. 
 
Figure 33.  DGK contribution to lipid metabolism in breast cancer cells.  DAG can be 
generated in the plasma membrane after activation of PLC.  In the Golgi, DAG is generated 
mainly from ceramide (Cer) by the action of sphingomyelin synthase (SMase).  DAG 
accumulation directs PKD to the Golgi, where it is further activated by PKC.  PKD induces the 
lipid trafficking from the endoplasmic reticulum to the Golgi apparatus.  This promotes the 
transport of the full-length form of the SREBP-1 transcription factor to the Golgi, where it is 
processed by proteases.  The processed SREBP-1 enters the nucleus, where it activates 
transcription of its target genes.  SREBP-1 phosphorylation, possibly by PKC, prevents this 
process. 
 
DISCUSSION 
 
	   97 
b. By limiting DAG levels, DGK might control the synthesis of several 
phospholipids, including PtdCho whose cell levels correlate inversely with SREBP-1 
processing (Walker et al., 2011).  PtdCho can be synthesized directly from DAG; DGK 
activity therefore limits PtdCho synthesis, promoting SREBP-1 activation. 
DGK can also regulate PtdCho indirectly by controlling ceramide transport from the 
endoplasmic reticulum to the Golgi.  Ceramide is transported to the Golgi via the CERT 
protein, whose PH domain allows it to dock to PtdIns-4-phosphate at the Golgi 
membrane.  Once in the Golgi, ceramide can be transformed into DAG by 
sphingomyelin synthase, a reaction that consumes PtdCho.  DAG accumulation 
eventually impedes ceramide transport via CERT PKD-dependent phosphorylation, 
which could lead to PtdCho accumulation. 
c.  Finally, via regulation of PKD, DGK might control oxysterol transport.  PKD-
dependent phosphorylation of OSBP inhibits oxysterol transport from the endoplasmic 
reticulum to the Golgi, leading to oxysterol accumulation at the endoplasmic reticulum.  
The full-length SREBP-1 protein interacts in the endoplasmic reticulum membrane with 
SCAP (SREBP cleavage-activating protein).  SCAP has a sterol-sensing domain that, 
when endoplasmic reticulum sterol levels increase, inhibits transport of full-length 
SREBP to Golgi, impeding its proteolytic processing and activation	   (Brown et al., 
2002).  This mechanism operates for both SREBP-1 and -2.  Although it is less 
dependent on DGK activity, SREBP-2 activation is also impaired when DGK is 
inhibited (not shown). 
We found that DGKζ is the principal contributor to this effect.  DGKα modulated 
DAG signaling effectors, but might not regulate DAG metabolism or does so only in 
very specific contexts.  We recently reported that, in the TCR signaling system, DGKζ 
activity responds to DAG generation	   (Gharbi et al., 2011).  We propose a similar 
mechanism operating in tumor cells.  DGKζ has a MARCKS homology domain that 
overlaps with a nuclear localization signal.  Phosphorylation of this domain by classical 
PKCα has two consequences, it promotes nuclear export of DGKζ and it triggers DGKζ 
recruitment to membranes, where the enzyme is active.  Several lines of evidence also 
suggest DGKζ functions in the control of vesicle and protein sorting (Rincon et al., 
2011).  DGKζ would therefore be more versatile than other DGK for integrating DAG 
metabolic and signaling functions, which constitute a network, that controls lipid 
distribution in cells (Figure 33). 
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2.2.  PA generation is needed for maintenance of the PI3K-Akt-mTOR axis 
DGK not only consume DAG, but also generate PA.  Although PA functions are 
less studied, it is thought that imbalance of PA levels can contribute to progression of 
diseases such as cancer.  Our data indicate that DGK-derived PA contributes to stability 
and/or activity of both mTOR complexes (Figure 34).  This concurs with a previous 
report on the contribution of PA to mTOR activation and complex formation (Toschi et 
al., 2009).  Analysis of various breast cancer cell lines nonetheless showed pronounced 
differences in the sensitivity of these complexes to DGK and/or rapamycin inhibition.  
Highly malignant MDA-MB-231 cells maintained significant levels of mTOR/Rictor 
complex after long-term rapamycin treatment, whereas this association was impaired in 
the other cell lines.  Treatment with R59949 alone had no effect on mTOR complex 
formation in the MDA-MB-231 line, but disassembled complexes to different extents in 
the other lines studied.  This suggests that the distinct rapamycin sensitivity of these cell 
lines reflects sensitivity to DGK inhibition, reinforcing the idea that mTOR and DGK 
operate in the same pathway.  The “rapamycin resistance” of MDA-MB-231 cells, 
evaluated as S6K phosphorylation, is linked to elevated PLD activity (Chen et al., 
2003); the lesser sensitivity of these cells to the DGK inhibitor thus suggests that other 
non-DGK-derived PA pools also contribute to mTOR integrity.  In MDA-MB-231 cells, 
DGK inhibition affects mTOR/Rictor assembly and Akt phosphorylation only in the 
presence of rapamycin, suggesting an additive effect of the two drugs.  DGK-derived 
PA might also contribute to mTORC2 localization at the membrane.  SIN1 (SAPK-
interacting protein 1) is an essential component of mTORC2, but not of mTORC1; it 
helps to maintain the mTOR/Rictor interaction and also interacts with Akt, thus 
bringing the kinase closer to its substrate (Jacinto et al., 2006).  SIN1 has a PH domain 
that binds several phospholipids, including PA and several PtdIns species (Schroder et 
al., 2007).  DGK-generated PA can thus assist mTORC2 localization at specific cell 
membranes bearing its substrate, Akt. 
Rapamycin-mediated mTORC1 inhibition relieves signals that restrain PI3K 
activation.  Many studies have characterized this negative feedback loop in which 
mTOR and S6K block further activation of the PI3K-Akt pathway through inhibition of 
IRS-1 function.  Although initially characterized in insulin signaling, this negative 
feedback is also observed during signaling by other growth factors, including serum 
(Manning et al., 2005; Parmar et al., 2006).  Correct regulation of this loop maintains 
adequate homeostasis in normal cells, and its triggering contributes to rapamycin 
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resistance in cancer cells.  DGK activity participates in this feedback loop since, as we 
show, long-term rapamycin treatment leads to DGK activation and concomitant DAG 
consumption.  This observation suggests a role for mTORC1 as a PA sensor, controlling 
DGK activation to precisely regulate the mTOR-Akt axis.  Mitogens such as serum and 
growth factors promote DGK activation (Avila-Flores et al., 2005; Baldanzi et al., 2004; 
Schaap et al., 1993) and PA generation (Chen and Fang, 2002; English et al., 1996), 
which lead to mTORC1 activation mediated by PA binding.  In “full PA-binding” 
conditions, mTORC1 would inhibit DGK activity to restrict mitogenic responses.  
mTOR and DGK would thus regulate one another, similar to the mTOR interrelation 
with PI3K (Figure 34). 
Our results show that, in addition to maintaining adequate mTOR activation, DGK 
regulates Akt phosphorylation, also through mTOR-independent mechanisms.  This is 
demonstrated in the experiments using rapamycin-treated MCF-7 and MDA-MB-468 
cells, in which Akt is phosphorylated in the absence of mTORC2, but is blocked by 
R59949.  This DGK dependence of Akt phosphorylation is enhanced when PI3K 
activity is upregulated by rapamycin-elicited feedback.  DGK inhibition also impaired 
Akt phosphorylation on Thr308, which is strictly dependent on PtdInsP3 generation, and 
on PH-based membrane recruitment of Akt and PDK1 (Alessi et al., 1997; McManus et 
al., 2004). 
We suggest that, in transformed cells, PI3K activity depends on DGK metabolic 
functions.  Early studies in fibroblasts showed that Src- or Erbb-dependent 
transformation led to alteration of a PtdIns kinase activity (later identified as PI3K) 
accompanied by increased DGK activity (Kato et al., 1987; Sugimoto et al., 1984).  This 
close relationship between the two enzymes might in part be due to the fact that the 
PI3K substrate PtdInsP2 is generated from DAG through the biochemical pathway 
referred to as the PtdIns cycle (Jenkins et al., 1994).  DGK-catalyzed DAG conversion 
to PA is the first step in replenishing PtdInsP2, the PLC and PI3K substrate (Bunney and 
Katan, 2010; Sasaki et al., 2009).  Adequate maintenance of this cycle is vital for cell 
homeostasis, and alterations in PtdIns-modifying enzymes can lead to disease (Wymann 
and Schneiter, 2008).  Our analysis of PtdIns intermediates indicates that blockade of 
DGK activity drastically reduced PtdIns-4-phosphate and PtdInsP2 concentrations, 
confirming that DGK activity is needed for maintenance of PtdIns cycle components 
(Figure 34).  Low-dose lithium treatment is reported to reduce inositide phosphatase 
activity and to cause accumulation of PA that is recycled into the PtdIns cycle (Dixon 
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and Hokin, 1997).  Low lithium chloride concentration reversed the effect of the DGK 
inhibitor, maintaining Akt Ser473 phosphorylation.  Our data thus indicate that DGK 
activity is necessary to maintain fueling of lipid substrates for PI3K. 
 
Figure 34.  Model of DGK as a key molecule controling breast cancer cell proliferation 
and survival via the PI3K-Akt-mTOR axis.  DGK is activated by mitogens/RTK, probably 
through phosphotyrosine docking.  DGK-derived PA is necessary for correct tyrosine signaling; 
it activates mTOR and replenishes the PtdIns cycle.  PI3K is also activated by phosphotyrosine 
docking and requires PtdIns recycling to generate PtdInsP3 and activate Akt.  In a feedback 
loop, mTORC1-derived signals restrain phosphotyrosine docking, limiting DGK and PI3K 
activity (top left). Rapamycin-mediated mTORC1 inhibition relieves this feedback loop, 
enhancing DGK and PI3K activities (bottom).  By acting on these interrelated pathways, DGK 
controls breast cancer cell proliferation and survival.  DGK inhibitor (DGKi) impairs 
phosphotyrosine signaling as well as PtdIns recycling, blocking PI3K-Akt activation.  Tumor 
lipid metabolism is thus reduced, with a concomitant reduction in growth and survival signals 
(top right). 
 
In these experiments, we detected no changes in radiolabeled PA.  This PA might 
derive from a non-DGK source, probably PLD, since MDA-MB-231 cells have high 
PLD activity levels (Chen et al., 2003).  PLD-derived PA is reported to accumulate 
radiolabel in such assays, but at difference from DGK-derived PA, this type of PA does 
not enter PtdIns resynthesis pathways (Whatmore et al., 1999).  DGK-derived PA in 
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these cells is therefore not essential for mTOR complex formation, as it can be replaced 
by PLD-derived PA, but it is essential for providing the PI3K substrate. 
In addition to the requirement for DGK-derived PA for adequate PtdIns resynthesis 
and mTOR complex assembly, our data also indicate that DGK activity might control 
PI3K activation by promoting its binding to RTK (Figure 34).  Phosphotyrosine-
dependent activation of PI3K is needed to relieve the inhibitory function of the 
regulatory subunit on the catalytic subunit; this is normally abrograted by PKC-
mediated Ser/Thr phosphorylation of RTK or one of its scaffold proteins.  Although 
DGK modulate PKC activity, this does not appear to be the mechanism by which DGK 
inhibition reduces phosphotyrosine-linked PI3K activity in transformed cells. 
Using RNAi-mediated knockdown of DGKα and DGKζ, we found isoform-specific 
functions in the control of the PI3K-Akt-mTOR axis.  Both isoforms were able to 
modulate mTORC1 activity throughout the cell cycle, but only DGKα was implicated 
in the control of Akt and tyrosine kinase activation.  We suggest that DGK-derived PA, 
as well as that derived from PLD (not shown), would activate mTORC1 directly, as 
described (Avila-Flores et al., 2005; Chen et al., 2003), reinforcing the concept of the 
PA-dependence of mTORC1 activity.  Inhibition of mTORC1 as a result of DGKζ 
depletion also helps to explain the DGKζ effect on SREBP-1, since mTORC1 is 
essential for SREBP-1 activation, and suggests a role for DGKζ in the integrated 
control of cell growth and metabolism. 
A report from our laboratory suggests that class I PI3K products (PtdInsP3 and 
PtdIns-3,4-P2) promote DGKα activity (Cipres et al., 2003).  In our tumor cell panel, we 
found the highest DGK activity in those lines with constitutive activation of the PI3K-
Akt axis.  We also found that DGKα interacted with ILK.  As mentioned above, 
whether ILK has or lacks kinase activity is debated; some studies suggest it is a 
pseudokinase with scaffold functions (Fukuda et al., 2009), although other reports 
indicate that it is an atypical Mn2+-dependent kinase that phosphorylates Akt Ser473 in 
a PI3K-dependent manner (Maydan et al., 2010).  ILK interacts with Rictor (McDonald 
et al., 2008b).  Independent of its function, we propose that DGKα is recruited, possibly 
via ILK, to locations where Akt is expressed, and contributes to the generation of local 
PA pools that activate the kinase that phosphorylates Akt Ser473 (ILK, Akt, PDK1). 
We show that DGKα has a specific function in regulating the non-receptor tyrosine 
kinase Src; through this mechanism, this isoform might also contribute to the 
propagation of RTK signaling and Akt activation.  Experiments in endothelial cell lines 
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showed a strong DGKα effect on receptor-mediated tyrosine kinase activity (Baldanzi 
et al., 2004; Cutrupi et al., 2000).  Very little is known about how DGK activity 
promotes tyrosine phosphorylation; DGK-derived PA might inhibit specific 
phosphatases (English et al., 1996) or, as in the case of mTOR, stabilize certain 
interactions.  A scaffold role is also possible, as DGKα associates SFK (Baldanzi et al., 
2008; Merino et al., 2008).  By interacting with SFK, DGKα might relieve the 
intramolecular inhibitory interactions of Src and activate the protein, as described for 
other proteins (Playford and Schaller, 2004).  DGKα also interacts with the protein 
tyrosine-phosphatase-interacting protein 51 (PTPI51; (Stenzinger et al., 2009)), a 
partner of protein tyrosine-phosphatase 1B (PTP1B), which dephosphorylates the SFK 
C-terminal tyrosine (Tyr 530 in human Src) to promote Src activation.  PTP1B is 
overexpressed in breast tumors with high Src or tyrosine kinase activity (Egan et al., 
1999).  DGKα-mediated regulation of Src via PTP1B could help to explain the crosstalk 
between SFK and DGK.  Finally, DGK activity might also be critical in the formation 
of specific membrane compartments, whose distinct lipid composition would allow 
RTK firing and signal transduction; this hypothesis concurs with data that indicate a 
role for DGK in the trafficking of clathrin-coated vesicle (Antonescu et al., 2010). 
DGKα activity is also regulated by tyrosine phosphorylation.  Assay of DGK 
activity in phosphotyrosine immunoprecipitates shows that it resembles that observed in 
total cell extracts.  Most of our cell lines with an alteration in the PI3K-Akt axis 
overexpressed RTK or an RTK scaffold.  We found that DGK activity (likely to be that 
of DGKα) is coupled to the HER2 receptor in a HER2+ cell line.  Increased tyrosine 
signaling, and possibly PI3K-derived products, might therefore activate DGKα activity. 
Current therapies based on the use of rapalogs and PI3K or Akt inhibitors normally 
relieve feedback loops that trigger RTK and ERK activation (Carracedo et al., 2008; 
Chandarlapaty et al., 2011; Serra et al., 2011).  We show that long-term DGK blockade 
does not activate ERK, even in the presence of rapamycin.  In addition, DGK inhibition 
or DGKα depletion impairs accumulation of the HIF-1α transcription factor.  This 
protein promotes a transcription program that drives tumor growth in hypoxic 
conditions, and confers radio- and chemotherapy resistance (Harris, 2002).  HIF-1α 
induction is highly dependent on mTORC1 and mTORC2 activation, reflecting the 
DGKα contribution to the activity of both complexes. 
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3.  DGK offers new opportunities for breast cancer treatment 
Our data show that, by acting on several interrelated pathways, DGK is necessary 
for breast tumor cell proliferation and survival, and suggest DGK as candidate targets 
for breast cancer therapy.  Inhibition of DGK activity or reduction of DGKζ levels 
clearly compromised breast cancer cell growth in vitro.  We found that cell lines with 
oncogenic mutations in the RTK-PI3K axis (MCF-7 and BT-474) were extremely 
sensitive to DGK inhibition.  In untransformed cells, PI3K activation products are a 
minimal fraction of PtdIns species, and the PtdInsP2 consumed is rapidly replenished 
after receptor activation (Hawkins et al., 1992).  The oncogenic activation of the RTK-
PI3K pathway is quite a different situation, as it requires a continuous supply of PI3K 
substrates, principally PtdInsP2, whose synthesis is highly PA-dependent.  Cancers with 
PTEN loss of function (e.g., MDA-MB-468) or K-Ras-activating mutations (MDA-MB-
231) do not respond well to rapamycin (Weigelt et al., 2011).  Our data nonetheless 
indicate that tumors lacking PTEN are highly sensitive to R59949, and that DGK 
inhibition prevents oncogenic Akt activation, as well as the Akt activation due to 
rapamycin-elicited feedback loops in K-Ras mutant tumors.  DGK inhibition might thus 
be an effective chemotherapeutic strategy for the treatment of these especially resistant 
malignancies. 
Inhibition of DGK effectively retarded tumor growth in vivo.  This effect was more 
prominent when R59949 was co-administered with rapamycin.  We have observed 
DGK activation following long-term rapamycin treatment, and therefore DGK-derived 
PA might promote new survival pathways that allow tumor cells to overcome 
rapamycin effects, including PI3K activation.  Together, this renders malignant cells 
more sensitive to DGK inhibition. 
Although its effect on in vitro tumor growth was modest, we found that DGKα 
depletion impaired tumor growth in vivo.  This might reflect the distinct DGKα 
requirements for 2D and 3D cell growth.  DGKα appears to act locally at sites that 
normally involve cell-cell and cell-ECM contacts; indeed, DGKα mRNA levels 
increased when cells were grown in 3D matrices in vitro.  Although tumor cells are 
assumed to become independent of this signals, ECM trigger proliferation and survival 
pathways that involve integrin-mediated activation of PI3K and the focal adhesion 
kinase (FAK)-Src axis (Guo and Giancotti, 2004).  Inducible depletion of DGKα in 
MDA-MB-231 cells abrogated their growth and increased their apoptosis in 3D 
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matrices, although residual cells were able to grow.  This finding reinforces a role for 
DGKα in the transduction of signals from the extracellular environment.  On the other 
hand, DGKζ-mediated control of the lipogenic metabolism of tumors might be 
compensated in vivo by several factors, for example, DAG hydrolysis by tumor lipases 
or support of tumor growth by diet fatty acids.  This effect was described for 
monoacylglycerol lipase (MAGL), for which reduced tumor growth was observed only 
when mice were maintained on a low-fat diet (Nomura et al., 2010). 
 
Figure 35.  Model for the variation of DGKα  and DGKζ  levels during transformation of 
the mammary gland.  DGKα levels are high in the normal epithelium and drop during the 
transformation process, allowing proliferation.  DGKα levels must rise to sustain invasion and 
migration of malignant cells.  DGKζ levels increase with transformation and help sustain the 
lipogenic metabolism of tumors. 
 
Based on our data, we propose a model (Figure 35) for the contribution of DGKα 
and DGKζ to breast cancer progression.  In untransformed cells, strong DGKα 
expression confers a tumor suppressor role on this isoform, probably by maintaining 
cell-cell contacts and epithelial polarization, and by restricting proliferation.  During the 
transformation process, DGKα levels must drop, although certain levels are maintained 
and promote tumors by supporting signaling through the RTK-PI3K-Akt axis and 
contributing to malignant cell migration and invasion (Chianale et al., 2010; Rainero et 
al., 2012).  At this stage, DGKζ would increase or be maintained, to sustain tumor 
metabolism.  This model is reinforced by our preliminary analysis of DGKα and DGKζ 
expression in human breast tumor-derived samples, in which we found higher DGKα 
expression, whereas DGKζ levels did not change.  Further analysis should nonetheless 
be done; in addition, higher DGKα levels in breast tumor biopsies might not reflect its 
expression in the epithelial compartment, as this isoform is highly expressed in cell 
lineages, such as lymphocytes, that infiltrate the mammary gland during transformation. 
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Our initial data allow us to propose DGKα and DGKζ as candidates for therapeutic 
intervention in breast cancer.  We anticipate two major advantages of DGK-directed 
therapy.  The first is that long-term DGK inhibition did not activate other oncogenic 
axes that could lead to resistance to DGK-based therapy.  Secondly, we show that both 
DGK isoforms contribute to tumor progression in breast cancer cells, although their 
function in the immune system is inhibitory.  DGK inhibition might thus retard tumor 
growth while activating the immune system, an advantage compared to other anti-tumor 
therapies. 
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1.  Pharmacological inhibition of DGK blocked tumor growth in vivo.  The DGK could 
constitute an efficient drug target for anticancer therapy. 
 
2.  Breast cells expressed DGKα and DGKζ, but expression patterns and function 
differed.  DGKα was strongly expressed in non-transformed breast cell lines, whereas 
DGKζ expression was higher in tumor-derived cell lines.  DGKα gene expression 
correlated inversely with FoxO phosphorylation.  DGKα levels and activity increased as 
cells became confluent, suggesting a function in the formation of cell-cell interactions.  
DGKα expression varied during mouse mammary gland development, reaching its 
highest levels at the onset of puberty. 
 
3.  DGK attenuation of DAG metabolism in breast cancer cells was crucial for PKC-
PKD activation, maintenance of the Golgi integrity and structure, and correct processing 
and activation of the SREBP-1 transcription factor.  This function was executed mainly 
by the DGKζ isoform. 
 
4.  DGK-generated PA was indispensable for adequate Akt phosphorylation; it 
controlled the activity and stability of mTOR complexes and supplied the lipid 
substrates for PI3K activation.  DGK activity maintained phosphotyrosine signaling and 
was coupled to the HER2 receptor.  DGKα and DGKζ were upstream regulators of 
mTORC1, but only DGKα controlled Akt and Src activation. 
 
5.  DGK inhibition impaired tumor growth in vitro without activating the signaling axes 
that promote acquisition of resistance.  DGK activity was essential for cancer cell 
survival and was triggered by rapamycin-elicited feedback loops.  Cell lines with 
aberrant activation of the PI3K-Akt-mTOR axis were more sensitive to DGK inhibition. 
 
6.  DGKα depletion had a stronger effect on tumor growth in vivo than DGKζ 
depletion.  This might be because DGKα was crucial for cell growth in a 3D context, 
since its expression increased when cells were cultured in 3D matrices and DGKα 
interacted with ILK, a protein involved in the transduction of signals from the 
extracellular matrix. 
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1.  La inhibición farmacológica de las DGK bloquea el crecimiento tumoral in vivo.  Las 
DGK podrían considerarse dianas farmacológicas eficientes para la terapia antitumoral. 
 
2.  Las células de mama expresan DGKα y DGKζ, pero su patrón de expresión y 
funcionalidad difieren.  La DGKα se expresa altamente en líneas celulares de mama no 
transformadas, mientras que, la expresión de DGKζ es más altas en líneas tumorales.  
La expresión del gen de la DGKα correlaciona inversamente con la fosforilación de 
FoxO.  Los niveles y actividad de DGKα aumentan conforme las células alcanzan 
mayor confluencia, sugiriendo una función en la formación de las interacciones célula-
célula.  La expresión de DGKα varía a lo largo del desarrollo de la glándula mamaria 
murina, alcanzado su máxima expresión en la pubertad. 
 
3.  La atenuación del metabolismo del DAG por  DGK en células de cáncer de mama es 
crucial para la activación de PKC-PKD, el mantenimiento de la integridad y estructura 
del Golgi y, el procesamiento y activación del factor de transcripción SREBP-1.  Esta 
función la ejecuta principalmente la isoforma DGKζ. 
 
4.  El PA generado por DGK es clave para la adecuada fosforilación de Akt, controla la 
actividad y estabilidad de los complejos de mTOR y aporta los sustratos lipídicos para 
la activación de PI3K.  La actividad DGK mantiene la señalización por fosfotirosinas y 
está acoplada al receptor HER2.  Tanto la DGKα como la DGKζ regulan mTORC1, 
pero sólo la DGKα controla la activación de Akt y Src. 
 
5.  La inhibición de DGK impide el crecimiento tumoral in vitro sin activar ejes de 
señalización que proporcionan resistencia.  La actividad DGK es esencial para la 
supervivencia de las células tumorales y se activa por los ejes de retroalimentación 
desencadenados por la rapamicina.  Las líneas celulares con activación aberrante del eje 
PI3K-Akt-mTOR son más sensibles a la inhibición de DGK. 
 
6.  La disminución de DGKα es más potente que la de DGKζ para el crecimiento 
tumoral in vivo.  Esto puede deberse a que la DGKα es crucial para el crecimiento 
celular en un contexto 3D, ya que sus niveles aumentan cuando se cultiva a las células 
en matrices 3D y la DGKα interacciona con la ILK, una proteína implicada en la 
transducción de señales de la matriz extracelular. 
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